var title_f2_38_2656="Lap adjustable gastric band";
var content_f2_38_2656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laparoscopic adjustable gastric band (LAGB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows how the stomach will look after lap banding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2656=[""].join("\n");
var outline_f2_38_2656=null;
var title_f2_38_2657="Thick intertwin membrane";
var content_f2_38_2657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thick intertwin membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 242px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADyAaUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Uor6u+E37PvhDxZ8O9E1zU7nWFvL2EySCGdFQHew4BQnoB3rzn9pL4Y6H8NrzQYvD8t/It9HM0v2uRXwUKYxhR/eNAHi9FFFABRRRQAUUUUAFFFFABRRXYfDDwnH4w8QT2c8zxQW9ubqUpjcVDomBwecuD0PSs6tWNGDqT2RdODqSUV1OPor3Twj4W+EOuatFpJ1DxK2ozsyRrEVA3KCTkmPpwa8n8badZ6R4t1bT9NMxs7a4aKIzMGcqOOSAB+lZUcVGq+VJp2vqreRdSjKCu7NeRh0Vr6Nok+qW1zPHuEUJVSVQtyc9vwp954b1G3TzUiMtuTgSjgfjnp+NdJiYtFSzQSwNtmieNsZw6kHFRUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUoBJwBkmgBKK0rTRL+6R3S3KRoQGeQhAM/Wu10L4cRXEYm1LVIli2bysHPPPG4/h2oA84oqa7t5LS6lt5hiSJiremR6VDQAUUUUAFFFFABRRRQAUUUUAfod+zrz8FfCv/Xs3/ox68R/bjP/ABNPCI9Ibk/+PR17b+zpz8FPCv8A17t/6MevEP24j/xOPCXr5Fx/6ElAHzDRRRQAUUUUAFFFFABRRRQAV2Pwr8YL4I8Vpq01mb22MTQTW4fYZEbBxn6gVx1FTOCqRcZbMqMnF8yPZZPif4TttX03UfD3gyHSJrOZnDwkM7q0bqQWJ9XB6dq8r8QX66prd7fIrKLiQybW6jNZ1W9LtWvdQgt1BO9gDj07/pmsaWGhSlzRvfzdy51ZTXK9j2X4caIun+GY5tQhlPnHzfLV9u7Pr36Afl71o3ek2LW84iu7eGaQl1gDfMfz71yUkl7azLNFNI0WOVMuQBjpg9xVV9093ELqeaUkeZtdtu30roMhLm0uI45kEkzxKciOSMMDXKX1sk1yMWmzg58s4DN/T6V22oXkvkRLIGVScsEYKxH1rk9beKEEWkLIHwxLHJHuR6UAUJtFdbVJ4y2McqRk5rNktZo8742GBnkV0cN8w09o5njUk4WRTVWVXmUocrsHMj5II9qAMEIxxhSeM8Cm1pSRyKoYhQ5G0IvB9jT0VEb99GSrLsPy85HegDKorQS3jfcyDeqkZ4xgfnyauxaTDcszwuwiA3bf4gPpQBhUVsLpUSSqLmSWNDn+EZFXE8M+bE0sd7EF6qrD5se4oA5uiu9l+GeossBsLy0ufMAJGSu3Pr1qvd/DjWLbePPsJSvURyMT/wCg0AcVRXTWXgzUbt41SW1jaQ4USFlz9Plqe68BatbTGJpbJ2Bw2yUnb9eM0AclRXSz+D9QitknE1pJGzbco5OP0pF8I3m6PzLmzRXbbkuePfpQBzdFdNJ4UcRNJFeRSIJPLBC43H25rQPgWS3sheX1yy238RSPn8OaAOJor0LTvB+nXVvNNbtc3UaMoyzCNvcbcdafqHhjTA8ENhErArud3kYseeQOQM9ulAHnVWrbT7y6UNa2lxMpO3dHGWGfTIr0jTNIWW8Mw0xLWKFdiuFXB9z3/Gtjw4skGoTQwKrRiMkqH2gn1X+tAHnKeCteKO8tl5CqQuZZFXJPpzzWjdeA5bCYR3+oQbiu4Lbo0h/HOMV38WjS3F4sSTS+UuZY4SclG9C3cVUuJrF7VIpWkjv4JW3MkZIZh6560AcfYeFLSecCMzMQ4ASbjd7ZHat+08NOElk0+0+XOA8ICgY6/M3NXLe+tLm2nnmdyqIB5ZbZn1Y46fSiO9uLeEWtrcySI/zwqv3jn19qAMw2tzpzpLcRKGRs53bg6n1Hc1oy3FnZwOdPMgIG4lOSCfUHgCmhInSWSZ7m4uEIIAAAU/1FOF3DezLBJKI3fG8sNoAHZfcmgDzXxMRLfLcKH/eqA7MPvOODz+R/Gseu18U29t9mu4ot6mB9yIz988npzkVxVABRRRQAUUUUAFFFFABRRRQB+hn7OX/JE/Cv/XB//Rr14f8Atw/8hvwp/wBe8/8A6Elew/s/My/BnwrhmH+jP0P/AE2krxb9tZidZ8KZJP8Aos/U/wC2tAHzXRRRQAUUUUAFFFFABRRRQAUUUUAFdj4U1C7NkkLSxLb2pkFuDEoId8FssBuP3BjJIHOMZNcdXrOgLZ6Z4as7Z1aa5kUyyR+VghjyRuIzwMfrQBWsLe6nR5ptLiYKDg7v9Yeuai02ztdTedr62uEmQ/IzZbaPTjtWvbveXOpyW9jIIkZAyR5LLIPb0at610uI3qLHf3en3wTBimT5XoA4DW47VQywtI0YTCOWJUN6CsVIlu0BkkeIQ4RztyTn+dd/rMjWheC909GlkbZHMeEY9jjtWVbeHNQtU86KLM8h+b5SycfSgDl7jRbjTon+0WskttN8wlQcY/Gm24XzFNtCwDALtfLZ9wa9E0u9hgVV1G1mupunzElV+i9vxqDVnstQv4SkUltJHyyCLZj8fSgDiNT0u9jQyK48liCxXH6d6ZHbtExQsrRlQ+HG4t7fWuluGiW5+dLYuFJKsSR7ZrPuvNVIrWNYIpXbcrqSfl9fagCnKIwI1t7XyiSMllIyO9PMYjmL2c8azMQGjKnj3rdha4silzdQC4lT5VAYEY9sd6htbP8AtTVLh1glUNgkZwMenHegCDQtHl1C8uBMouEVgS2fmB9MelddZ+G0urCSD7JEfIIe4eMfPH6BfWszQ9Gt2uZ5Z3azd22oUfliOgYV3ej24/s55rqaZXyZAzjaj4HAOP60AVRDbafqEAs4prnEYJZWESj2Pqfask3F7by3sk8cglQ4j8xN4Ge3GP1rp9V1Brj+zrmDKQIodtqAkH39vwqta65eyreXWbdoWf8A10qntxhUPBoAwNNt7uSzAhSBgvMjrJ8y554U9KQ2ks63zWLZnRBGWYgMw7k+uK1pZXlleaOzM86jfIjIE3D+8COBVATLqSvG1klhIzbI03/NJ9cdqAObe31MxQMkMkkcTFRJGRtx2IFVdRMsV6Fm8pFfkPnc2Twce/vXqen2S2Ma6Y8kQjkT944fcynHpXD64lpaiOEKnlxswEzJgH6kdaAOf06O2FyRxFCB1Od3Hp710tk1pcxt8tx9hUcCSbJY+uD0qro1naRXZaaZDcEEIu4EY9avSROrQIY/OJJiG0D+L270AOsjb2fmRs0rQscoYz90nsfWsq6NklzcbLIKWHlxQyykMX/ve2a1r8i2lIt9OMsMSCEGUbRu75HrVvTorPWLW3hmSQx2+FcyJyxHcHrigDIg1JY7yCIpcWcygQvIuHjZj2zUd0fKCm1ghykh+eInueSAetbOq2z2+lrDHKjWxkPlHyj5zew7fjWVJClhb2sssM1yQPL2ryUHsBQBo3Oo2h0ae5El1HM3QRnaW/DtUOkPYJZlruOVpps+ZPgER59TVaNYbhgXdUdEMixu2Ni/yLVoRtZLpZ+zuwiQABM/O7HrmgDJ1mytJ/PhE7XAjXdEtsq4wfWktNHig023MBZZHjKiaP8Ah47019Xg0+GW5t7eSWaR9hhJPykcfNTTcTXER3HyFLAMGbaHJ6gA5xQBkPGFg8yQfu1/dliHCE/3m96vxm3NpHGsSblXKJjDOexwea3dQ061gt4Whso7dZAEMkjny8+pH+NTSiTTLNgLm3mDjCyRIC2fQEcUAY+hXJt7Sa0ubWMPco0dxuQMSDyQCemcdRXkOqW/2TULiDDBUchdwAO3t09sV6zYNHbajGhkmNy7fOpBOF9veua+LVlbR6lbXVnEybk8uYlSoLDp29P5UAcDRRRQAUUUUAFFFFABRRRQB92/Ae7kj+D/AIWVduBbv1H/AE2krx39siZptX8LF8cW0/Qf7a16l8D7tI/hL4ZQqxIt35H/AF1evJP2uphNqvhkqCMW83X/AHxQB8+0UUUAFFFFABRRRQAUUUUAFFFFAGhoVidR1SC3BVVJ3Oz9Ao5Ofwr6LtJ4Lix2332O5nUddvySV5D8MdGublp9QhjDoriDlhjsWyOuMFeler3llaaXeALYqVeLe69Ux7HsaAKVtLcSSPcaTZxwKrYZEwdy9yoq3PJp51JZJLVmvHwSyN/U4xWnptimm6W72s0rrIxlUg7mXPoT1rm9Skm1kqIp5sBiHYR4fIoAPEWmx3Tst6bqOHcWV5MFkP8AskcEGl8PtepAsWmSf6OvytHMMOPcGpI5bO++ypc3F/LcgmFlclVz7cYrVOlnT5FLwPHCE2iRTnH1oA57VdMkhnSbY7XUk25XPzY9Qc9qxdY066udaY2jSfOoAY42D1B7/hXSf2xs11vthdrNMBHiw5P1H+FS6hqWj3Gs27WlnPFu+SSTyyvHr0/nQBxFxbNBLcyTyjbE6qyFR8zfX0qW8jmkuYgqrIHTZKIRyo7HJ6V2Yt7K2ur5YoVnDgMyyc5+lYcVgbvUglu7WkMykeV1IP48YoAqW0Eclu8FhLGlyF2mIcg+/wBa1tOs0SAMv2pZUO6WNzx/+qql9olzazx26xo5kf5lWMD5fXg1spBNHbqj6t5YjIPkiP5semTQA25l0/ULgP5AaSUCGBR8plb+8fYetaFxp40NoI7SO4uxIoSYsGcA/wAWMdABUOgQ2mlOLiWA3XmMczA5CKf7ox+eK6C9S8e4tW0yZzC+WI2/KB79waAMNkml1O0ktlWC0X7kEwYNNj8OPpVu2sxDdNPcwF7OR8+SHDDd6gdqr3+reXeRJKypaxtiSC4cFvqOelaOpa7odjEksEaiCQYCJJuJOOuM8fWgCbUEtr2LyrRQdxIlxIY1VR688/SuQvYLKwJuJLK2khQCMh8ksSeDk9B6Yqlb+MLZYry1ZUctmRbiYkkDsAOn41HJ41tbqWxW5jWVrcYaN4yVc9jkUAbdhJvhllgQwyIpAjHU/wC/n+lQWtlfy2kN7PpweA7kliD8OPUE1k6bqVtqF3PIzqlwJv4HK5TuAD6V1+ravZG2j07TWkaV1xEQ2UJ9zQByf2HyreaS7hihAclF24x6Bcck+9WdISS4aKe63TSvxBKDt2sOmV60mlCS4u2kupZJBGvlOEB2D2BPf6VsWVxb2Wpxw29sHZsMzR5Z09y3SgDntV/tKW+YanPGJQoJDdPxUe1aOjWupR2EDP5PloGVYmcAqSeD64rT1TSltPM1W1sJ5EyWdp5AwJx971rnHvbKC0W5d3kuRlixJ5J7c0AdLHp7wWUB1uxMil8BxPkc+gA6U9xHqt5BY6DjT0VNzyBM4GcYxXml54vvdSjPmtIksThky2BGB6ev41d0vxnc2SQ3MO4sG+dUUEEdye5NAHpGn29vYTT6XNMlxKxLIRCN6k9SxrL1GwvLHSJRgtk/PMkXEuegLdjVjRviSsitLZaDHHeFcfaZgMn8etc7rniXxDe2kltJfQ2NsrHIKZdmPZecUAbHh/wqWEt7qaPDbEb0XzPmJx09xXIanFa2l/CzTKhnlxOrchVB9exx6Vm6zq8pgVJ9dmuJEXYqBsr/APWrkZ55IrkNNOskZJ5+9QB7Qk+mzW/mCZEgjPy27MSJfTvU0OoeH9EsJdQWGaW9YcRsoWND/sivDLu4uDAhe5cxg/KnT8asw3tzJGyO8soP3Q5H86APS017TZrpdQS2dWblS/OW9MVDrcUvibS7+DdNPdmPzUVIwEQpkqOcYzyM+9eaC4e2nVo2wyj5wx4P0rb0rxVeRs4jlZJH4Y7chRQBxdFW9UVVv5jGhSNjvVSckA81UoAKKKKACiiigAooooA+zfgxNEvwr8Nq0igiB8gn/pq9eVftWOr6n4c2MGxbzdP98V6F8If+SZ+H/wDrg3/ox68y/ad/5CXh/wD64S/+hCgDxKiiigAooooAKKKKACiiigAp0bbJFcBSVIOGGQfqKbW14RsWvtdgAhM0cP7+RMZyq84I7gnA/GgD0/wpdS25uL1M2s1wfMnjtrdUjjZuflXGAvPQdK6+w+0T3MCxypqCzKfM3EBNvrjsfpWHpaXYtTPFZzNFOfm8iXBH1B6VBqU1zpaiSL7XbMTuHmIrK3tlaANm6Gp2azWfkww2DkqFaXcAfVTjIPtUnh+SCW4aO2WV5mXZJJIvDEcZIH8688v/ABlJPKYre4liiIxKj/MC3qvpWJNrd7Dl7aeQbmzuB2lfxoA9n1Swaygtohf20sYfLqx2bj2APJFM+1Wk96sL3Vz5g+9FJLgD6Y4IrxufxLqU0Ic3BaRPukAEP9c1SXXLtgfOvcTdwRxj2NAHsWuXGi6PIJLKCOUq5aYupYjPX5hzUVjf2rpLJBcqk92MxSSNlAvcexrxuPW5Y1fy5T5jnDsTwR9PSqtxfzYO5F2Z4C/54oA9avL2DSvNXT7r7ROeZyUyuO/IqlB4nS4k8+VBb2wG1WU/ePqfSvL49QIlYqWVGHzIzHBqJJXjnVRIIkB3AAkgd6APWbjxLbNcLcsty7QrtXAJVvxNUL7xqgfZZr5cZ5wcEEn3/qK4efxDdFlUyK8YGNgGA31qjcXkc8LL5KoC2QqjkfjQB3M/i5Tp8OLp4bhfmDJgA89Md/rVeHxhq2Y5bXUZxub51LhR9K4fyVaTYAoyM53dKkkKn9w+C64w/agDZ1bWZ9RmeRJpWdmIdWbIP0J71nT3IhMUsMm9l/5ZlcAfWt3SfAHijWdBk17S9Fkl01C+XjkTI8v75CFtxx3wK5yOb5Zy8hUk/d2bgaAGi5TLtkqH6qAfl+nNTR3MtqP9HZwCckscgj2qoIg0TupCY7Z60jbxsV2JQDI44oAvW91NE4aWUbjztYZz9TXRaFqks4jD+aMEnMZ2lR7Z7VyCzMpUMuMdOOKufaLpIkZi+wdCpwuPagD0SxuolsXY3c8EBfJhA35PqDW7pF1b212r3NvuMqjy3LhGK9xj1riPDd6qwhbiCS4UnjzHwPp9a6uLyW1CKS+tRZwRKTHk7wDjq3pQBtazqdjfafcW+n3FzGsHz/ZpHyCRzyfSuSk1XTLjTp1msWV2XJKDbtPvXS33iPSLfRfs1kGuCoOSkWM++TXl+r3Et5LHchmU54GOT7EelAFmaztHjAnLJHt+XDAqfypkmrW1hZQrZiPzE+8B0b35qnqDP9hdZJlSVhxH2+grHceZabpJcAcBcZ59KAL99rd9MAVnKpJyFj4xVJ72+mbZLLKWIwQT2pikMI2SQ7kAwPSoruV2cAjBX8896AE3MVkTCAA5NKXijWIx5ZgMkHoDSzW1xHaQXEkEqWszMiTFTtkZcbgG6EjcucdMj1qBhjryfWgB7ys+RIxwenFPcIUUROcDrk1GzK5yV2jGBzmiOJ3dQo5Pc0APf5HA3eaFHbPFWrSIbwG3IJh3YYI96rbjBIU3KRjkr3pEUyONjAsTwvpQBe8Q6ndavdJcX9w1zPGiweYQB8ijCDgDoBWTWl5avLNHIxPy8dBz9KzqAEooooAKKKKACiiigD6m+FbsPh3oWGbHkt3/AOmj151+0YxbUNCySf3MvU/7QrtvhleNH4A0VAinETdT/wBNGrgfj/OZ7/RSVAxDJ0P+0KAPJqKKKACiiigAooooAKKKKACu38BWcaWN1fTlgrOIgY3AdQOScdccjIriQCSAAST0HrXZWaSW+jRJNHKsajKqefmJ5I9M0AdJcandWrqkGosICNwUdPwP9DXP3fiPUJXaP7ZJNGc587njtxVISzvGI4QQA5wpByP/AK1RWtlcztKkS5dAd+1NwI9qAMed2Nw5l+Usc4HSrFsWncxBgQ4+UM3Q1saPoIuixnnVHBwnmcfmDW1YeHbganDGVhbg8KM7ffigDndO0pjM8Rz5n+yeDRe6SwlDiOXC/e3p+npXpOg6HpBEy3peCbdgvJ8pJHQqTXc6b/YF74VuopI445RIALh8KXIPWgD51tfDeo6jM32W3Oz1I2gfX0rah+GniiZHa304zRoM7ozkN+NfQ0H/AAi9tKPPkndY4uRBhkTPcnGfzrBOm67Yrcnw/eyHTHk8xJcksFPUYHWgD5w1LSbzTp2hu7aSGVequP5etVI8iQE4z2ya+k7LQr7Ub5I9SihvLWMOsbyRlSxPPOa5LxF4G0pvtOY2s5YwZM5BVfbHegDx2aVZUUFFDDqQKjJKoVLkY/hrf1TSJ9NcRF4trgMvYgH1zWI7NkO6gheNw6GgBI3jEBDAeYTwSOlWZLWbyTcyAHI+UYyDVZ4HwshUbGP8NaKTTxReX5n+jkcHqRQB718KbhbbwR4CmHh7UtVvv7Wv4oLmxlZWsWcRqZCNpVzg5AcgfKevNeHeKtLi0PxZq9j9tF7Fa3csCzr/AMtwrEbuCevXrT9P8VeINIsGtLDXdTtrFtwa2gupI423dflUgc96xpFLFXZ1UEYUDnFAD2McqSLEhDdQDwBUYuJnhVMZUcA4piqTMwiYMcd+9NUucoDt9ulAFiHY7YeRQF4BHBNSJ5bRoBuG07ZGBzx7VXWPfIFjwpIwAec09fMtyI50GwHOP/rigDqNFhacLGN3lRSAq4HWu9+xrc3P7v7P5pUbkkkzvH07V5/oc9z5X7oK0R5WMvg/jXTWVxdWdtI1+iMhHyoq7j+dAHT28Gp+IrU2rQaVYJG3lcnn68Vla58OUsFDXOtWjtIOED5K/rXO654oYWxVIJIty/extOfeuO1O/e4C7CQAM7i+TmgDU1ews7bUPssd0G2Y+fgj86xrmWFLiTysMOgz6+tVAjeaN52E8jdzmmkbuDnzCaAFchi5LHdwfxr0P4V6Poawah4j8bRtL4ftWWwSNMbprmbIG3PH7tN8hyR0HXkV56U8vKvtz7g13mg/EzVfD3g6x0Xw0x026S5muLy6EcTi5DbAgIZCfl2nv/FQBP8AErRLjwx4V0TR7vDSWupaiquPuyxlbVkkHHRlKsPY15xuI7816d8WfGsHjXwn4OuHES6tbLcRahyu+aULAPOYKBjcFwMj+DHavNUh8xV253ntjrQBH1IbH4AValtpRhVAJK7io6qPelt4zGxWQFW9cZxU7PFG+0kuzdSTj86AMzawYcHI56VoRTwwqAUPmsM7yc4qy1rOdpRlljdfvHgL+NULiJ1wuxeD99elAELvubLs24nk+1JcKiykRtuXqKUJ85DEEDksOQBT3RZIndFIC4A9/X+lAFaiiigAooooAKKKKAPof4d3USeCNHRi2RE3Qf7bVw/xymSW90jZniKTqP8AaFdR4CZR4O0sFgP3bd/9tq474yEG80vBB/dP0P8AtCgDzmiiigAooooAKKKKACiiigDW0S+nhiuLFQhtblo5JgUUsdhJXDEZXk9jzXo3hafSbqSNdY8yCGQAI45APcmvP9AjUxsoI82Zgi5GQAOuT1Fek6BYJHaOjfMyHaAx+Rj2we340Aejx+CPD4t3l0nVYp3dCwwwbdx6Vzuj/DjW47WTUdNaBVdy0ilsvge3SsbS7IJf+UFeG7kYgJAGDJ9a9A0bRNQO+W21WSK7C4+zuxZZPrz/ACoA4TWQoXy7m3jjmjOFk2Zz6gim+FdSS0W4R4IU3thXVfvfQ9R9DWrd6JrGn6gzTIZ52cuIwu4Ip/ut/Q1o3cyQ2Etzc6Q6yIOZPIxk+5oAw9Wg1CdvPkks3sU58mVRvH+fWuZl1udYfLNvss3O3AU/LXTXPiCWZEjlGmzxOmdvlZaP65rFju9L8ldxmhZ2IMTH5Cf9kY4FAF7TVuNQ00wxXMSkggEP5YI7A45Fbul6lcW9vBaqJdw+SVluMAEema5CNd12YLdpFtUIO7aCM+grSvZ2BAJj2qM4kQKxNAHaX2q39mIxE0twqMHwMM6f7QPf6VbvZIdYtrWW4Kyzb/MEMcALOP8AawOP0rgIpL3Ulb+zma2mBDMUAVhj37iurmfU7e3tzFcBbeQbZRj53+h9aAOS1rwvY6pqVy1oXtWzjExHJ9FB61wviPw5JpcogwxUnKMhDEfUCvSItTs7S5aO4e9Fq55Ev3Q1P1bRBqc0E+lKZ1b5ZVTk7f5UAeKXe+NPLaF0cdcjqP6VWhkDqYml8uLPQivZta8GWUwjuVs7q5hzh3B4DDtnrXK6r4DkulNxpdv5KL1jZ/n/ACNAHDxhJisYYRgZ2krwarlvLcqSzKDgEGtfVNKn0sDzYHRl+8XA5rOmiM8QkiCcckA8igDctfDOnXFpDK/jDQrVnQO0MsF+XiJGSrFbYqSOhwSPQnrTx4W0rGP+E38OE9c/Z9R/+Ra5uCR49wycd+M7qeJBFCylSGJyGBoA6dfC2lKNi+NPD4duR+41HP8A6SUi+GNNV1J8beHWVTna1vqJz9f9Erll8x03+Yd69AetIZZldD5h8wEFcUAfUnxB+D/hLQ9Lt9esfEdroE08KyLYX7vLE5IB2xZHnfmrt6gdvFy15PasCI7U5ONzHJ+n19659Lq81TUGvNTubm9upHBklupS7ufUt1NdLFKHjjDabHIBx5mS5/OgDndYS8kESXjfuyenBG78KwpIipCvGcA7eOpNdTqLLPdNGyrC8Y/dqke0n3qGz8MazI3mWkHmYG/I+8fwoAz9L8Pajqd5Fb2NuXkY7VLHGD7+lehXvwX1my0U6hql3ZpGvJVWJb8q7X4f+Bda1T/SRI1tKFG9UkWPYMd+Ca6/Xfh7LcxCz1HVm+RfMVYpWcn60AfMKaJaw3ksc8jzIn3WiGc/Wsq8t4I5gISwj756ivXpfDf2JNSNqjvIj7PNIG8f8BqBvDWnR28F1eT2hMw2GNHG5W9/U0AeRCDcm9gyx54wM4qzbtcEIsSEKxwNoya310iP7RNbsrkqTsU9OvrW7pnhUTQ+bcKHOP7xyv0oA5I2LXEyxCVDKf4NuCK9O8E+BLZrYXN/ZiWTbwCa0PBPgmytrstNa3s13KcxPtJX8T2r0i68Of2fD5uq/anijG4RRYCN7Eg5NAHket6XbLrCWtxbxJEQVWC3YFgvqR3/AA4rnNR0rzZ5tO0yxla3RQWfaNw+tejvYx61rBk0pZbJAdiokIVm9iTVi+8ONE7Q6jf7WnP+rhx5jAepWgDw5dMitRN54cY4EbLyfxFMhuLiG2udPsY/Kt79VWdZI1YkK25dpPK89cYyOtevanDYxILDTbRYWTlpbhcY98Hk15xd6fL9sndnX7UuT5kXQj0xQBw0qGOR0bqpINMq9q6k3RkZt7N95sYBbvj9Ko0AFFFFABRRRQB7F4O58Labx/A3b/bauW+KQxdadx/yzf8AnWv4WmkTw9YhXYAIeP8AgRrnviHI8lxZb2JwjYz9aAOQooooAKKKKACiiigApVBYgAZJ4ApKvaPEZb+PChgpz83SgDQs9OnYExqv7oYbrnNbmj6hPbmNQklw0Zy8LfKPwq9bWtzpAFy7MpxyyDcrDtmukur2z1LTFk1TTY0mxlZoT/PpQB1eleLrGfSTL81peRYx8oLf/XFaV/4jle3ic2YuXkXqmY3U+oIryU6jBEFBgmZ4z8rjkgfnyK3rfxTd6PZQq0wlBOAHiycH+Ed6AOusLzxBOZHuXLqBiMxOGK/72efxqjdMsl0IdSmusz8pJ5m5AR2I6VW8P+NrV4ZUu7VS4BJUAhj9e1dJBLpN1CizWhtoZl3Lht3X2HSgDldThMskcNkllO4IzKDsPHcqev4VmXVx9peWLU7e2kmjO1JoOD9dven+Ixp0Op7bWaQuoK/OCFA9qz7WNbJY7iO6UuDwTIGVvfBoAvWFrDbKn2ed5nLZWIfz5q8+iW/mSajfuIsjIhkbniqtjJYO8kgguJwww80a/wCrP07VXvJTaiNtPnkmDNhxcA5HsO9AFmVry+nWTRpkW2UBcsOfcY71a1C7udPt47S6jMk6ESxOmf1Hal0Y6i9u+2JLGJWyWeMjjuQTzW3p90gvftOnWkepAEK81xKCSe/XoKAMa5uraSWO/wBgdHXy50A3bCe+D71oeGbm7sbt4rOGG4t5ecKNrJ+PerPiYSX9mscmkJp8zycyRSKVkUdgR3rnLPU7m3vvskCTRxR9XQgsPzFAHpOhXmo6XevcXsDWdqvzBYfnDepIPFdH4j1jRPEGmKq263k864SaKMKyH1JIrw++8aatbyNaBZb1HbYDOdv17elem2Hj+2bQU06PRUhljjALFwR09uaAK6/CdfEW+BEjt1QZeV1yzeuB2+teU+MfhRqGgm6kgfdbLkZ7kV3+heJ7nUfEEsVm00oYBZQsjEqP6V1GtxteWk9ldx3ELqu4EsGUj60AfJ00Jgfy2j+ZRtK5pj222OOWNCCTgrmul1/Q7q0vZZmgZkMpC5Xgj1rnJ7iXLCVPlU9Qen0oArqwEpeTOQeABRtjDj5lbcevp9asCES4C7AEGWZqS3iQzcRvIzdDjjHrxQBdEOJY15MmAQY+6966mx0czW++C8njgbnymByT7Vm+FLTzbkeU5LRtlfl+bPvmvU9OZtPl8l2JGMu8gWMD6etAHDvoaWds5S3eS5cZ33J6e4HWmx+MtS0eEq0YWUkKWQYAHtXT+ItAa91AyaPfqbhx8/8AEv8A9auYm8F3t7fGCaea5lH8MSHbn69KALdl49v5bZ5TdSwS7v3m1j+9Udjg16HpnxysrWzUwaaXkVAsjScDNeaXXg46UjPeIYsjG0KWyfwrGk0oQbzNCzQYB8xGwv0oA3PGXxCuvEGpPdRSpal/keOFdoK/WuYee6vmcQGNox0JIG36e9H2BfNaS0txMpPHzfKD/jXS+GvCp1GJpbuUWkf8Ixg5+lAEnhbw4bm4gu7vV44UXkJcnJJ9+a3vEl0LO5ikt/s0qIRiWMkbfw75q5pWh2c2pRRpGL9UG3zAhTb75PFa2s+FrKyKCwUu3JLM4IU+tAHSeA/EYbe+oWssgjAJYsERR6AdTXReKrq1utMja0t/s8kzBlVlBc+nHauJ8LT6foNn580Qu9RGWkmCEgen0q5psOteLNRBCvHE2TIZflyD0249KAM57y+k1q2tJraQs24okJyVHqRU9zqVzpmpC1iXfdMvV4AWX2Azz+NdZD4a0PQLhJbzVs3KAgBpMsAewArK1fxDp+lzNJp2lF7knb9pnXaOfrzQBy1tZSLdXF79siuLtiS8bQYww/Gub8VwLLYmVt/2mQ/6RNkDA9B7V2OpR3WpF7a2kQXkw3OYmCIgP+13/CuH8TadJpNmILi8Ejk9U/eZ+tAHmeuafCsLy27lwvzZ7Y71z1dTq1w8rtA3z7uuFwo+grmp4mhlaN/vKcUAR0UUUAFFFFAHf+Hrxo9EtFCKcKep/wBo1i+NZzPPakqBhG6H3qzo11Gml26MWyAe3uazPE8yTS25TPCnOR70AYlFFFABRRRQAUUUUAFd3olsdW06N7i1t45FgW3hWGIR71TJDMAMsxJOW74FcRBE888cUYy7sFA9zX0JaaLpX9n2wi3wNaxhRFc5McgA/hY9O/f8KAOM0G5vtMikg1DfJaYw0bLwPzqOZdNvI5hayGCJeWVn6+1elCx8PalZsu5YZiuGiaXI/A1wt94atobyX7BOm6MEfZ2PJz79xQBkeGL+y0/VXW90/wC0WzEAEnJx7GvWtS0rwlrukMtlcNb3CpkxSHlfoa8eZbq3kjceWY5ThUToD6Z7VGJNTFxMojdAwwoUkgfiKAI9ctV0hy9owkjYlWkWXIb2I9a6Dw/44i/s37NeXc0aqNqEJwD2FcTdWStHI4dnnVsNGcjmqPlNG2wq6OwyApzj60Aeww6pYSW0TXFpbzxy8yIQcsexFP1HwpY3Dw39hBJArL80Z5CH1ryZr+4jiEEjsVGGWRev510Wm+I9Ya3AgvXkK9mOSaAOp07VJPD0l8t1H5nRti8L9az11+EzByIVDtuG2Qkr/OuZv7+4llW71FnSZTtCFOCtS2evWdhcJIlksrSDbucAKaAPePAHiG1upGgubJZ0A4eZvMVm/EcV0GoPY3rfabHTYrdUfypoUAZX9wBzXlHhTxbYxXVva6hZxhGkG7ySQAp+le4JZ+DxbZsbvUIkz5gECyH5vyoA4jUfCOt4N7e2d0ljA++JYeQvuBWQun70kub62N9bsfkDR4lUe+Oa9G1TxHf2c620Wuuts8JZmukDbPbGAT+JrMsrz/hINLSO+k+VCVS5gHlF/wDax1xQB51ZWRGtJcS6U0mkQD5Um3KS3tmt+A+CtReUz6de21yDjMSsCD9RVHxXpWp2MkFsb+SZJHP2dxMPl/3we30rah8Krq1sLvUNWhsJEQL5aMCXI6/nQBx8cuj6Nqlw/wBquYSpzG29tx+uMfrT9Jv4r/W5r+TVnYou1UlJYH6iuf1rQI7LxGwkDxhoyweaPhvqKt+GPDsd3eN9mLWqLkyyyw/e9l54FAFT4gWyzSGaWRcN9yO1JOffFeXXojhlaKQNKvU7eCPqK+iLHTtOk064LrCPK3Rq5PzEfjXh3iiKzXUpXtt5QSEem715oA5oRlm/iCg88YIFdBp9ncDYIpY4U7zdyMdMVUsVmm1FJIbZ5OflXn5hXqPgzw5q+oXVxJa6Wg2KAXeMny/p60AM+H2hm4lW5nmEMEa7vtDLhc/j1r0G8iWKAS3VzNLbqNxeK1IRh6ZNTWi6pb6aHtdHgMFu2GWd9rMw6kAZpt74i+0mzhuzPK0zbfKiGVX9cmgDE8qG7aFLKBzZStxHEuGRvX60lrpxsLhIJb5otshLNJIzSBfQp2re1rZaW8T2L3ZlWUFYjFj5vUcc1LYahqsMs32m0JFweLiZVSRBjuKAMK4gtpbm5uJJIdXiBwqtGxSL68YH5Zrn/EPgmdtKkuo5EWPd5gVD8ij0Ga7hZoEI04RQvLOSGuosgp7t2qt4j0u5Fs0P2gTW6KMIXKMT6j1oA830/TILGeGSPc6D55AxwDXplje+H2SATSCKZ0zGpwA1eUa/DqixKoZeZNiKx+Zh757VeitLtWgGqX8UMIAV+nI9BQB110rvqCRFhNZk5WOOTav4kdaLC8lGrrDcbFh2tuhli+RR25xU0OiaBaWcDWXiB0eP5guQ2c9qs6LcaLHeo1+11qFxMxCxEnH4jpQBQGqSRwmHTnikSWT5naMLGgHXGe9adneXS6oZLvz4bXy9sLwhtp9elWdasrGacPc6DBBA52gmYNj04FX9Ols7UJazlWj6QgdBQBymtXK2l4LrUpZntVP7vBO4/wC8amh1V7nTLhrGbz4XORHcLnj2p3jHw/qOoXUQs7mJYFO5ogOcexpdFsfIszBfWolmkJKu+5AF980AczeTXF1A0cULRK3/ACzhPJ/3mHQVwus6pcCVoExEEOGUJn9a73xp4huNJt/sVpBbJC+VXYMV5g7S3GnvLMDtBJOW/pQAtsBJeNM/71VUZYjof61T8YP/AGhetqyQxRLcOdyRRiNFPbCjoOD+VT2zXDW6RWpkO7naEzXf2nhBNT8JXsP2jffmAyRw5AwyjIAA5PTGKAPF6KU9TxikoAKKKKAN7TmUWMQLKDz39zVPWiDJFgg/Keh96rxcxr/h71FcfeH0oAiooooAKKKKACitzwt4dn8S3FzZ6fKv9oJEZYLdhzcY6qp6BsdM9elY00UkMrxTI0cqMVdGGCpHBBHY0Adp8JNDfV/FAnPywWKeezsuV3/wA/U5P/Aa9/svCz6rA8P25I1f/lnkMv4BuleZ/CW7bw94VmnjitJJNSc7vNTcSq5AXIGR3OPeu1SdLLSjdqZLe7B3D5iB9AD2oAvSeFoNJP2TUYLi4iUfJLGpfH1ArBuLJpHdLbThHsbb5ijZla6+w1W9+zR3cl5HIkoGzIKkE9jnrXM+I7qbyLmaSKeG5VuoYADnr7igDh7+1k0q+eSOJbmJSXMUnIB9aswT2t/Zu8CxwzIufJjXaQfY1Z/datqsCmPbdsu2RpeI/wAOasapoU0epRh7RAAuwvBzuHrgGgDhdQjBVGghSVWJLF/vbvc1nSIkdyfPgUOF+VVbr+JrvrTRQs8yJbPNHGcGReoJ9RWXrXh+4trgx3s2ZHBKKqg/LQBzui3H2W/8q/ULFKfl3bcfnXvPhK58Fix2XtlbF1X5hlc/UGvn6W2whivJJ+GwgHb8cU2SKdnjKygmLrkYGPf1oA9b8Uaf4Y1R5m063mt4eQCZ1YD8M15xf+FlbK2F7FMsf8O3nHp6Vl3Dzyz4FyNqjOyJiVP4U6zlntAZizkv/CDgj3xQBqWGmNHAhC7mU4USOFK/T0rqNMv/ABBp4+yE3RU9C7Fh+BU1y1vdySzZuxHJCRjIXlf9oiu00rX/ALIlsv8AaKkKBg+UGB+uaAFvfEmpLmKWN5bpB8hfkH25rZ8K67qFzC0M3kwMBjEylSp/CtaHWbTUWhW9hsbhZGACpEVJ99x4BrZT7HpuoMkoMCOuFEsXmRhfUkdPzoAo6bqDPN9k1FYJ5B92bacCtW3i0yy1yCfVbaC4g2lQVk6N2IFcj4mttS/tAPpsmnz2kg4aInn6jPFUdDGqaJqLXF2HvLIn5rcbio+nBoA7q+isW1d5LSx32cjjdHcISCfUNg1c1+ys44I44pIbR5WGYg2VYd/fNZsnixbC6gn0myaMS4WRJSdg9ue9P16K31RU1O+vjBJD/wAsmAIQd/loA4fx2bDTg/2QL5St8jPKQV9h6ivKbm4U3Ly3LRSRF8hFXP48V3HxB8QwX11DbW32a4tVO3zVHzA/SuXt7CKWfYrOwB5GzlvagDX0Z5mihfTmDyFsrEsfyge57V7l4AmudO0lku79bS4Yb5DGu44+pB/lWB8OvDVnZ2MmpIWiYDHkogwPrnrTtf137FO/2MoryDHzMRk/SgBt7ffbr54dLvbu5gdyZZJJAFPtj0qhqWnWdwtvF9pSwvAxMbwv91R15pfD/huW6ke5jubcpICXAlBYt7Anin6fomnWWnPLrcjFhIwaCZ1K7fX2oAv2V00thJNdai06wnMW5ssuOM5HTPvU2m3FxcahFHfxMwPzA3Mu+MDsR71z10JrOe2l0VEFiQSLkrkN/snA/Wu7bURL4e877LY3FwE4QtnBoArX+s+XqKwWFvLqTKcOzxgLH7jb2qnqunsjteXWrweaww6LztT+6B1H1qx8PZIbi6kgnWMXJ5bZKM/QgUeN5beC5lsNMitVuwu+SWQEiMevuaAPJviCyxyW5hgSO2DYVxksW9Sa4+4a+ltybtmifGIy8mAR24rtPEHkNp0d3PeG4u0Pygphc/SvNtYvJr+dJLncrDq2O3sKANCDUJNOVXM2+5xtTYOBWto2oXBnWYXsgnwcFY9wjP0rDt7YXEv2azjkEkZUsVGWbPvXrngjwfPfRb0tLe0ULgtPl2P+FAGXPrtzDpqNq6zSs3+q5+9749KyJfEd1LAqSyS3GfmVol2+X+Ndh4n8NafZOrT6tK1wo2hV2n8AMdK4PU4Z1uD9gYsi/KVY45+lAFk+M72B3jS4lnB6svylfYnvTJvHtxNYNbFpHfOMliPzPWuPNvcNcXAjCxPGcFOpJ9az3tRATLcJ83ckkc/SgDfu7y61GJJZ2UMh42/4VVuLSW8+9kYXcADgE/SqGnmaO4URDesg2/cyMnsM12vhrwlJOGubiK4miibcVTI59PYUAT/DTRo7u9jaeznkZDncwITPqT6V6xqsul2ukvd3q2m2MbYVj6k/UVU0aM/Y/s8FpHDbMMKke4PMR1HqQO5pNS0x47dmns4ZXJ2xxKTx6cHg0AfNviu2Nvrt0fJEEc7GeOMdFVucD2HIH0rIr2T4peEI4PBFtrcalb2C58u5QIeEccE9gAwxz3YV45QAlFFFADgzAYDEfjSEk9ST9aSigAooooAKKKKANnQfEuqaAGOkTpbSMeZViQyY9NxGce1b3hDxZet4wnvtTsbbXr/UomtCb1C+C4C7+BzgdeM4zyOtcRXoHwYsZX8UNqscTSJpsZlyE3BXbIXIyPc8Z6UAemWen6NEqw2MjwoqqjA5GNowODz+NXZ9KvpSsF9dvcacRlHZVcZ7Z7/rWlfyWOtW6t/ZhS7x8tzbOoAP+0Cc/hzW3BbbtKjjvJbK4t0X5tqbXH15oAwtNtRot0udQeSGXGyAZAFO1zbqV2wmwpg5J3gY98dD+NN1GbSoo5TpRiubcL+8tmdkKn1HcflXGandzXUKzRJtVflLFmIC+jEjBFAHQ6aNM1SSS3CW0s9u3FzERET7EdGrQt41+3yxwRW1vcKuGLI2SPrnArlfDekxnVLez+2W8wnUuEiRcRn8etdddeHhbwT39teubhF2lVI+YegFAGbPpUlk813Y3wivpDzuBKt+FZ+v6ZLcRw3HiO8eZYxuje3TJUnsQB0ravVuILCCXUILu32jKGVMhh+FU1/0W2e5t4UmWTncJRwfTnigDhXtLRrtWW4K2jc75D1+gzV6HRxcX63ls0d3Gq4kjZR09QO9SfarmW7dbuwjuUzkC3AwPqe/4Vq2W+1b7RbwRCNOTExJYj065oA5+48P2Ou3E6288cVxCM4ijKY/3qz9M8GzQ3DST3MLqAeN5/Wu/u7TSZrZdRjsmtrmcfvPJkOSPQ81RfSrYOjM8sVsoyJpAX8v8B/WgDj7XRZRLJLboPL3ZEyH5R7epFF7bSTyxItoYmQ5YqQFP09K9PlFhY6TJNp066k0y7Snkghm9eOlR6TZiaw+y3AhEbD94JIypUn0Y8UAcPHb3MU0ZW4kbysMPMYgBv7voa7W3ur/AFV7Vrq3EDWoyHdgVb8KnXw3ZTsYprue6CcAIQwHpwO9bkXkQ6f9im02a5AXZmWIqw9+eDQBnpLa2ML3GqW9rdbn2hoY/m57cdaj1G1kkjjk0yW7tIWBBQLuXnvjrVzQrKzuYjNcl9Mu4yUIZfkYZ446VJqZjQSNZXEslyvAbOEP50AYdzCLH7BLdGV7W3bdKwAwx9cHrSeIfFVlq1m1rpkFu0pBCzFcEnH61neIdL1Ge5s21Ob7RBNkCHO1Ppkdat6Vam5gW10/TZI0jkw+YSSpHcGgDy6Lw7e3OqCEQj7bI3zERldvufSvUfh98NA0rXF9cGK2iIOG6lh3ye1du954V8O6cJ9Tsjd37cEyqPMY15x438fQ3s3l6aJ7VQuGic5GPoKANP4h+KrPT1ns7K8M6Y2tGE+QH1yMV5guoX+oQR+VOplDZSMfMw+hNZl1dy3EQkEKx7nyQjHBHrg0gv0g1CKVVaDy2BMu3J/IUAeq6DLeWdgsrx3EEeMtuhVyx9emale7spp0a/tTcW0jj94FYBT7jHFc3/wkdzqqmS2u7geTgq2No9/rXUaFf7rG7lub1bpJONpXJJ9wOgoA6dEuJkkTTtXgtraIAqHUEEegJqDSNLvb7UGmv4FkwcgK3lh1Hc4xn8q5G2uLCK48q2t7a+mY53OgRUb0BxW+wuLiwaTUnkikU/LDCx2+3PBoA6DVpNMll3ta/YLS1YEXUIBDt3Ge4rmfGOsC404T6G2yLdiS4dD847gZ71m3l4s8kdtq095BGeFjVsRkfgOtclq+sW8KzWOnxSywo2Vdskg/SgDA17UhFMIVVymcGVznrVPStOS9ui7STSAtnAXJC+pFWINFvNXuJRBFcTSyfwxKf8DXYaH8PPFcKROmlSRPnKmR8ED6ZFAF/wALeGJoZbS8ssNCxOS3ylfc5r2rQtQWwWOC+NmrdDIXDbx7ACuEl+HHi2TTT9vltIgRk7bg9f8AdAx+tZmo6Zr1rbiFLyO5nQY+SJvl/EDigCX4p69aQamot40ti3ImQqpPtg814zrepXVzfM8jCQynAx8px9B3969j0r4bP4jtzdXc1vbY4eWWTeT6jJPFdvonwz8H2BghkAvbwfMGgUhV9yf8TQB8wWlnqbwzzRpKgRgrADJP1NbNp4T1edGYQo8YIJfduIz6ds19MDwXocOrN/xKna127nkllO0t6YzzVG60y30s+VBBCLNmLssb8xj8eBQB5x4Y+FzS2Ec8uyyk6gGTcxz6ivXwbXRtBi0+3izOy7VOzcXPrgc1U0bXPscLLClokDnbEXRnbP1xisnU7rUZNYSHLqJj8zW8RyV9Cx6D6c0ANabXPtKSNBaw2o+WWYAI5HoAf8aravd2s+rWun2cm0Ocy3KSbio7gY71tGIjVUiVhDaInMS/O0jfT0rnoRcXGoXk1teQQKp2wxooDD6rjOaAL3ifT7PVvCGpaPA8lxbyxsjPOpBBHIOWHYgEH1Ar44njaGaSKTh0Yq31FfV9oIpRI+ssyxwH95LI7lpDnsvQflXgPxb0+3tPF091YyiW1vh54Kg4VicMvvzz/wACoA4qiiigAooooAKKKKACiiigAr1f4fLZweHFjhluLfU5WaXzVkwp7ADt0APOea8us4GuruGBPvSMFHtk9a76WA2zwhpWkgXC7kXaQO2fWgDt7e/vbdnSeGT7R1E0S8H/AHtvB/KrtzrVtbRqotXW9kG4yxSYV/Xr39sVzNjJd291HNY6g67fuozgk/XPFdZaa3I9+qazDbmBlxuMK4PvmgC1a3NiqNcwyGYOvzrOoyv0IGawbS+hW4ktlQwo7HyyynY2e1Xtal0PT4p7myMbq/QRNwPwrntMW6v4XEywG0Y7vMMhAX07cGgDp7DT/wCz7ImaBZUEnmLNDyUPptGD+NdNoWrLqEDM5W3lDYRk5bjuQa4LVltFVfI1C4+27MDbISr/AJf/AFqr6VM/l/8AEwvY9g7xLhlPvnmgD1DxBq97P5FktytwT92QgKoPowrPvbuYBLHV7OyMLLxJEp2j61xtnbQRStOt8ksTn+A8n8SetWJryGLe0dxdPAfvJNIXA+npQBVvTJb6oDNbl7Unaj27bEI9+9XYLq0hndLiCHAXKbpMN+v+NZ7X0V5G0tjbwwMn3S7bo5PwNSWGswiY2+tWtiNy8tBEGH0IoAisXmuLx7i0eKRCxVrTsR7+p+laEg1CyvrZY5YrZJ8gRoTtb254zVEQM0zQ6e7pY58xH2gAfmAauyyjU7iJby9sxGnAbBZs+4B4+tAGlHPaNppjmuXsTvIZQArMf9739qktdbtY7d7aCObBO3Ejs+8/Q8mpVnWaW2txb293BAcqYECAH1JJPNat0I5LWR5YHiwdwRlBOfVWFAFaziMjRXcumyLNEeJIlMRI/u+9dJPdiQw3f9myxuBhg0wGB9M81lQ6xNdWCQWrQo0nyk3RKY9609ZsBY+F3je5hlu2jx8spYsfagCS2he9Je2WR4C2XF18qr9BUN/YzX9yHinUyxHbDEsfmJ/wI4/WsbwdpGrNpy3VlexWCA8wTsSJPUsD0/A13Fvp97Ar3M8McSlf9ZasfKJ9cE0AY2naVNcajHbazbTrIGDI1o+7b9QOgpmpyzy313a6FLIfKG1hNgy59AOOPrVrQFvLfWLi5vribzHGER/kVh26Dmr+vztbwZQNDeSkBTawYzz0z1JoA831XSbuS2YXK2zXBPzRRJ84H94nnBrlLrwbd2VrJcFZJAp3CRpN2B7ivpLSLa0vdKjim0qcgf6wTxCPc3qRnJrEvtOt7RLqRIJ4dPydyCEcH2PegD53k8J314I59mUJBCxj7309TWjqXgqayksZDp95HBOcSb1K4+te52mjaTYW9nJbx3FkzHclyVEu3Pr6VFqupX2r6tFoi2zTEEM13v8ALTb7jrzQB5HaeF0F5giW1YY2iXLK/wBAK39F0PVILqSS3tIpLQEmeRX5c+2a7nXdKXS4maGKBLhxt8yNC4UepPX8qwJNL1Kx0kS6de3Vwz/M7+VhPqAcUAZ7p9itmgsnS53sW+zG3PmBj/tCsmJ9baB/NjZkgk52jr/sjFarzTRmKdtRmjuuhXyx847gYyaopqerHUraGKNrcyElCxJTHchSASaAM/XdKhvIFv7W4uLIs3z+dnaD3HNaOiada2Ol3MU2nHzJlOxo48B8j7xY9Pz/AAr0mCz0a4sRJql3CpUfOZmCg/nVWGHwzbzIY52kGf3Sqpdc+ozkUAU/h1oU0VjHJbaj5SIMN8iFPwzya29YjGo2vlfbpHckgMm44x7L0qMahHcyCWO5itmhOIym1tw9xjFT319ZiCO8vNRhDx/cV4WRc+/HNAEvh/SXitYpZ7xbVos7vtM+XYf7Walg1Pdc3PmqbiwKkJM3yjPfGBkiqVpDNfRi8ayzj+FyCh9CM9KL26uIVjNoLidt37wW7AhB6dMD8aAG6ffaHDayvDpsYfcQyxrjI/4FVjUtWW0sf+JdF5LyfcjEW4/mOP1rKs7iLXr9orqS2traI8qGBlkPvkcD6V0djFoKXDQz3EsjjhY2JwfpmgDjtOtdW1dZopbaYBQWjaSYhS/qRk8VVlk1OwtTYPab3U5luUJcE/zrtriW8Bna1tktrYDbEsh+/wDQD/GorHGnaaP7VlginYlvLiH3frycmgDA1DSNXvNDhcXhiaEb0jaPOT6HNXdOtoofD+/U9UQ6lKvSMdD2AArbsbKK9cSm5eZRyElb5V/4Dx+tNvtG095TJeXV0IlwdlvuAz+FAHBaPLqm6aBHSGdDho41O9l7Mx5/KruhyQ29xcbZbsAfI7i3DuX7/MOn0rrLvT4rXSrmW0jWzWZfkkOTM/1NYi2V7Y2Fldw3Ai8kZmEzcN9Pf60Ac9eeHtQhv5Lm7V5bFgWUyNiT8un415z8V/D66t4Om1K1htoptOfzm2Dl4zhWwepwSpr1OyuZ73XpLjWGm+yS8IrMCuP5VHro8PahdX0N7cNYx+U0B8qXDyIwwwwD3BxQB8aUVd1qxOmaveWRZnEErRq7LtLAHhsdsjBx70UAUqKKKACiiigAooooA29J1e1sLeAHTY2u4ZJHF0sjB2DKFCkElcLgkYAOWPPStzTfEVu0csdxMdrZIWUfp3/nXEUUAemxTTT2ufs0RhH8Q7fQ10Vrqf2DTFa7t1uLc8DzFII/GvF7a7uLVt1tPJEf9hiM101p471Rbd4L5YbyFuzoFI+mBj9KAOzv7uyltwljb/Z5Cd4Q8KTU1jrBSTNyzWx4RkCY4Pcg8EVx2meI7CTzIr0SwqQNjbQwU9wcc4rf0hxqkcXl6pp6gE4jaQFyPocEUAdNAiLObcx2ZhzujkjUqceorUFnp1ukr+U80r/e5BzWTdaVDpqpdvcOYwOER8gfSuasb3ULm6mls7kxqj8xsvb1NAGlqlxDZ3CxR2aQCY5Kum8H3AFYt1q80eoIIiHnc4aJRgMPXHY1ozawrSsNQGXUcZQ4/PAqlb6rDDdtcpawRhjw5XigCvCL97h1i3wwO2XRsEfWtlDd2EDfY1mJYZI8rdkeoqta6ulxPOU8pXP+etaf9sz2qqZI3k2jO5QDigCjZao9zdRpcOznOCJU8plHoAOtdRp4s1u3ihDW77dxVUyjfnzXMnUZNVc3KQWzKxwwfgt9O+a2dEVjE0c6zIDzHLgnb7E0ASvqN/DqDQokUdu3yl0Qgj3x3/CtWaw1qa1ikg1KMQQ/PsyRv/GsFbCe0klmlia5hOT50Y5X681c02G8u5kkFwj2o+7Gh5P1oA7S3vGl0cPJJPJIpGFjhR/wPXitzRdUupbIvd6VE2zgM8ZBHoRgGuW0uKztYJp5bdVZQfmWQKai0i61bWRJJCJXsQSFjMwQ4H060AdvDqmqRRx6jb2tvbOp2NGyl1K56+1O8QarfTwwXMLWtwR1itZiVIPXK5rldAvZNCmmNzp9xc2zn50iJYof1zWkviXRr87tO0yW0lLbQTHhs+4HSgDrLJNPv7SJzFL9pj+bG8zYPpg8VosRdPGt7FFDAOgdMHPrnPFee3Rv7VJJbtJlvmceSQSf++RzW4dY1maRbdrSN0RN0kjnBB/GgDpotIt01KS+TxDMjIm0QRyDZj3HenLLNcwF7i/tktM4ZWIZn+vauMlv49Vs5rNGNjejqdp+b8cdPpV3RNOvn0oWlqoVi37xnl3j6gYzQBtXNmUvJbpUb7AY8o0UhG36L0rMiSzCNdi/eQMP+XUr53/AgetN1zT9Wt7WGztNVhdW4mz+7dR7HORWdY6iNBuRaLp4m807VuY1OWb0LMOfrQBNp00dvPM97qVy8bHcizQ5A+uBWTrepyXM0biQtDuwFL5Rl9wOldbezapHZiOQ2qNJ1Urvx9fWuVN1IryWbWcUqqN0lxbtsCfUHofpQBl3qvZO8tnFNHGi72kQfIvspbofpV6bUNMuLa2k1fzLqYKGjDEb1HuaZfabc6tYsZp5RZj5gqyhs4qhpiw6pZyW4tFeVPlIkbYWA/nQBrWb5ukvDFaBB/q/3o2Rr7g8k1oa1qOlhFltGnn1AAbYbdd4P4AdK5K7t7IQC3m0NFEJzmCXfu+vpW18P5kgFzNLbvawFvlRlbgfUj/61AG/4cj1W81GPUL6O30q3RflgkUOWP8AexxWj4i8Qm6vY7WCKPUBEQCTAQmfQAdaz21Jprotb372nPIKb3ce3pXQ+ENNvNs+pX4CzS5VXnwDt7YA4AoAqXGi69qDRSrPaW1pGuSiBiwPt71b0m+eK0+xvM0MTAp5xRVHPU8mtK6treyWOzlvZHF03McBA3fj2FTaHZ6SJ5Ghs4JBCcIjvubPqQaAME6bNbIsNtP54J/4+SoUop64AHJqCw162sb6ewtrQRJABunnjw8je2R+tdjq7alNEUsUggc9SGGQB2HasLS7OS9hnur6cTTKSqwhBgEe+OaAFfToL2EXmqyxxRZ3GQjGPoxqaLTpb3yzoTQfZwQHmmJZmHtTtSNs2hMLyJY5iCERfnOe3HQmoLcahFpKF5Vt4FQFiSEJFADdbsxb6jDDZRQyXMg2s8jcD3bHNUL2xk0kQrdanBLG77miO4KPoAefxqrPrui2SfaL66WwQj5ri4kVBnsCW6Zril+OPhDSJbqDUGn1cl3CGBNyjHQEnAOT3GRQB6FqV9HPcwRwailxOy7o7KEBM+5Y9AK5jXV1u6vFM9pGVtiCsJfKE+gHc/WvF/FXxwF3qIufD2hQWhGMG4ctjrkbVx7c57V55rvjvxJrcsjXuq3Co4KmKA+Um0nOMLjP1OT70Ae9fELxnCIorG8ubWylgHnOpZWPH8IA6n2Fec33xTgtL1pdPtRfSDpJcRKik5Hp8xHX0ryZmLsWclmJySTkk02gDT8SazNr+sXGo3UNvDNMcssCbF/L+tFZlFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGjb61qcEbRxX1wEYAFS5IwOg5rTtvF9/EVZ47d5F6SbdrAenGP1rm6KAOr/4S15kH2pHeTdySwYEfTFSNrcV1FhDbx7Tja4K5HrXIUUAdlbTPYlkUp5R+bMOJFHucc1et9WfzgkjtNGx5CHCkVwFTR3dxGoVJ5Qo6LuOPyoA9Yim8PyPELm2Nq68xvE3D/Wtu11ZPKlT7HcJbgcOG6++K8asdevbNSEaOQdvMQHH0rfsPH97bRhZbO2mI7/Mv9aAPSLDWdNkhWNboQ722sG4P5Vr2Ohw2yM+kucuSTJvG0e+K8lv/ABlZX7or6cYUJ+ZgQxH04H86VvFlmU8q3e9tx0Dj7h+q5JxQB9BaHDpEltJbXdm97IRlnC5Gcdj0FVLDWZ/DZngSKEQNJ+5hkcO6j8K8v0j4kR29vHaLeJDHjGUDgZ/FeKfY+NMajPD/AGlaeW3IkkKBT+PBoA9UWXd4gguVuJYpHX96kK8N75qbVbaykuZGxLBvO8yvDkP9SK5jw5dWqMJ4dagljnGTENrIfXac/pVvVoLqVwtrLEmnZDSYmEWPXjNAG7Fb6lfGNrC8n8qPpGVJU/Q9RUF1cxi7gheNwyyAznzc/mWxWrb2dlFa21xDe6ktuoDCO3Uuh/TmniGNrjztJuY3nnO0R3MByx+h4oA0WvNM1TW7a3uIYprdI8q0JHyN/tFeP1qrra2um6vCLd5o7WQ48i1l3ySt6EZ4FaOk2+q6LPLLeRgW7LuO1FZifpwBVCRfN1V7zRLWRLiY5lW5jYKfccZH8qAGzRJZ3MjGG4t4Zl8wLcIs6q3oDzg+1azXcGv6C0E1zBINuNoT5lI9u34UyytNQ1XzoL2eR9n3441Cgfj1qWy8OQXbSNMoiKHaGgbBP+8e9AHFR+abk2RuCsURyXCOXI9Oe1NOjSzyPKsANqnKCSfZu+o9K6O98LWZuWT+1ltQnzeWtwsf598fSscW+k2U5tJdaguWlJJmi2y+X/s5YnmgCpb6ZearFJBcW0WnWqjapil3bvxqO30FdKBtY76ee6mP7tMdR7t1q7a634V025uY7zXLCS5h4T7TdpC4OM4Kn+dc/qfxM8MG8gfU7y3BUkYsHdyFz/fQYoA6OGyhlaOOF4o72Ej5WXeAfqe9dm2iySWqS6rbyXECAMQswiB/UflXleofF/wPZSxjTHuJoTxI8du7S/X5yo/WsD/hcvhm1di9pr+rbnJUSXAtxEO2MFs/Q0AfTGlz6ZHaRSQQIikfLGUyR+NQ6us+qXESSfZF05eWixudj/IV8y6l+0RPIrQWuhiS0Kj5bm6O5T6AoBkdPeufm+PvjDfMLT7Bb27ArHH5G/yuOoJPJ+uaAPrfV7zT9N06RQIiyL3A+T8egrAk1q40W3t7hrdIo3Yea1y4BVT3LdO/c18c6p8SPF+pxeXc69dqu4ufs+2AscY+YxhSfoa5q7vbq8mkmu7qeeWQ7neWQszH1JPWgD7b8S+OvDNs3lt4u0+ycqXYxSiQtjsAARzXBz/HLwZpaBLGLUbsygl3tYBGQ3vvI5+lfK9FAHuF1+0FqcMJGi6TDBKwYGW9na5ZfTaAFA9ec1w2s/FPxlq6ut3rdwqyKyuIQI9wPXOB+H0riKKAJbm4mupmmuZZJpm+88jFmP1JqMnJ5pKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigC5Hql/HGscd9dJGowqrMwAHsM08axqYHGo3g/7bt/jVCigC++sam5G/Ub1ses7H+tOXW9VVty6nfBumRcPn+dZ1FAGl/bur5J/tW/yep+0P/jUa6vqSZ26heLnk4mYZ/WqNFAE1xcTXMnmXM0kz4xukYscfU1DRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The arrow points to a thick intertwin membrane characteristic of a dichorionic twin pregnancy in the first trimester. A and B refer to the two twin sacs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2657=[""].join("\n");
var outline_f2_38_2657=null;
var title_f2_38_2658="Tropisetron: International drug information";
var content_f2_38_2658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tropisetron: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1980411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Navoban (AR, AT, AU, BR, CH, CZ, DE, DK, ES, FI, FR, GB, HR, HU, IT, LU, MX, NO, PT, SE);",
"     </li>",
"     <li>",
"      Novaban (BE, NL);",
"     </li>",
"     <li>",
"      Tropisetron Novartis (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1980404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Tropisetron Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1980406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Serotonin Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1980409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of nausea and vomiting induced by cytotoxic chemotherapy; treatment and prevention of postoperative nausea/vomiting",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1980405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justified;\">",
"     Chemotherapy-induced nausea and vomiting: 5 mg before chemotherapy followed by 5 days of oral therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justified;\">",
"     Postoperative nausea/vomiting: 2 mg shortly before induction of anesthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Oral: Chemotherapy-induced nausea and vomiting: 5 mg/day for 5 days following I.V. dose given on day 1; take in the morning at least 1 hour before meals",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1980408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Injection, solution: 1 mg/mL (2 mL, 5 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10440 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2658=[""].join("\n");
var outline_f2_38_2658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980411\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980404\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980406\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980409\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980405\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821061\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1980408\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10440\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10440|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_38_2659="Patient information: When a baby is born premature (The Basics)";
var content_f2_38_2659=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83622\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"         Pregnancy terms",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/8/29825\">",
"         Patient information: Cerebral palsy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1732\">",
"         Patient information: Having twins (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/62/22498\">",
"         Patient information: Jaundice in babies (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/29/18897\">",
"         Patient information: Newborn necrotizing enterocolitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/20/27970\">",
"         Patient information: Preterm labor (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/62/23521\">",
"         Patient information: Sepsis in newborn babies (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/62/8163\">",
"         Patient information: What to expect in the NICU (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/25/17813\">",
"         Patient information: Breast pumps (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/63/34805\">",
"         Patient information: Deciding to breastfeed (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: When a baby is born premature (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/when-a-baby-is-born-premature-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H877973627\">",
"      <span class=\"h1\">",
"       What does it mean when a baby is born premature?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A baby born before 37 weeks of pregnancy (3 or more weeks before the mother&rsquo;s due date) is called &ldquo;premature&rdquo; or &ldquo;preterm.&rdquo; Pregnancy normally lasts about 40 weeks, counting from the first day of the woman&rsquo;s last period. Premature babies are sometimes called &ldquo;preemies&rdquo; for short.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H877973642\">",
"      <span class=\"h1\">",
"       What causes premature birth?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s not always possible to know the cause. But some things that might cause a woman to go into labor early include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding or other problems in the uterus (",
"        <a class=\"graphic graphic_figure graphicRef82935 \" href=\"UTD.htm?7/20/7495\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Being pregnant with twins, triplets, or more babies",
"       </li>",
"       <li>",
"        Infection in the uterus or other part of the body",
"       </li>",
"       <li>",
"        Stress",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H877973680\">",
"      <span class=\"h1\">",
"       What kinds of problems can premature babies have after birth?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Premature babies can have many different problems after being born. In general, the earlier a baby was born and the less he or she weighed, the more likely he or she is to have health problems. But every baby is different.",
"     </p>",
"     <p>",
"      While a baby is still in the womb, his or her organs and body parts are growing and developing. Premature babies can have problems because they haven&rsquo;t had enough time to develop all the way.",
"     </p>",
"     <p>",
"      Some of the more common issues are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Trouble keeping warm &ndash; Very small babies can have trouble staying warm. There are things that can help keep a newborn baby as warm as possible, like special hats and blankets. Your baby might also be put in an incubator or &ldquo;isolette.&rdquo; This is a bed that is surrounded by clear plastic to help keep your baby safe and warm; it can also have a heater.",
"       </li>",
"       <li>",
"        Breathing problems &ndash; Premature babies sometimes have trouble breathing on their own after birth. That&rsquo;s usually because their lungs have not fully developed. Your baby&rsquo;s doctor or nurse will monitor (watch) his or her breathing.",
"       </li>",
"       <li>",
"        Heart problems &ndash; In some premature babies, a blood vessel that should close after birth stays open. In time, the blood vessel might close on its own, or it might need treatment. Low blood pressure is also common in premature babies.",
"       </li>",
"       <li>",
"        Infection &ndash; Babies who were born early are more likely to get infections. That&rsquo;s because they are not able to fight off germs as well as full-term babies (born after 40 weeks of pregnancy).",
"       </li>",
"       <li>",
"        Digestive system problems &ndash; Some premature babies have a problem with their intestines that causes diarrhea, vomiting, and sometimes blood in the bowel movements. This usually happens within a few weeks after birth, and can be serious.",
"       </li>",
"       <li>",
"        Bleeding in the brain &ndash; Babies born early sometimes have bleeding inside the brain. This happens within a few days of being born. This bleeding can be mild and stop on its own, or it can be more serious. In very premature babies, brain imaging tests are done to look for this problem.",
"       </li>",
"       <li>",
"        Jaundice &ndash; This is when the skin or white part of the eye turns yellow. There are ways to treat jaundice.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H877973695\">",
"      <span class=\"h1\">",
"       What treatments might my baby need?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on how early your baby was born, how much he or she weighs, and what health problems he or she has. Your baby might need to go to the neonatal intensive care unit, or &ldquo;NICU.&rdquo; This is a part of the hospital for babies who need special care.",
"     </p>",
"     <p>",
"      A premature baby might need 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A machine to help him or her breathe",
"       </li>",
"       <li>",
"        Extra oxygen",
"       </li>",
"       <li>",
"        A feeding tube (to deliver breast milk or formula into the stomach)",
"       </li>",
"       <li>",
"        Medicines",
"       </li>",
"       <li>",
"        Surgery",
"       </li>",
"       <li>",
"        Light therapy (to treat jaundice)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H877973710\">",
"      <span class=\"h1\">",
"       Will my baby have long term problems?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Some premature babies have health problems later in life, while others do not. The earlier a baby was born, the higher the chances of long-term problems.",
"     </p>",
"     <p>",
"      Some of the problems that can affect premature babies later in life are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cerebral palsy &ndash; Cerebral palsy is a disorder that causes problems with movement and balance.",
"       </li>",
"       <li>",
"        Vision problems &ndash; Sometimes, babies who were born very early (usually before 30 weeks) have problems with their eyes. If this isn&rsquo;t treated, it can cause trouble seeing. An eye doctor can check your baby&rsquo;s eyes and suggest treatments if needed.",
"       </li>",
"       <li>",
"        Problems affecting the brain &ndash; Some premature babies grow up to have problems with thinking, learning, or memory. Some also have brain disorders, such as attention deficit hyperactivity disorder (ADHD) or depression. There are programs that can help babies and children whose problems are caught early.",
"       </li>",
"       <li>",
"        Growth problems &ndash; Very premature babies are more likely to grow up to be shorter and weigh less than average.",
"       </li>",
"       <li>",
"        Ongoing health issues &ndash; Babies who were born premature might get sick more often as children or adults.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H877973725\">",
"      <span class=\"h1\">",
"       How can I get support?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Having a premature baby can be hard and stressful. Social workers and hospital chaplains (spiritual counselors) can provide support during this difficult time. There are also support groups for parents of premature babies. It can be helpful to talk to other people who are going through the same things. Try to get help from these sources and from relatives and friends. That way you will have support both in the hospital and at home.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H877973740\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=see_link\">",
"       Patient information: What to expect in the NICU (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/20/27970?source=see_link\">",
"       Patient information: Preterm labor (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=see_link\">",
"       Patient information: Jaundice in babies (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/29/18897?source=see_link\">",
"       Patient information: Newborn necrotizing enterocolitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/62/23521?source=see_link\">",
"       Patient information: Sepsis in newborn babies (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/8/29825?source=see_link\">",
"       Patient information: Cerebral palsy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=see_link\">",
"       Patient information: Having twins (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"       Patient information: Deciding to breastfeed (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"       Patient information: Breast pumps (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?2/38/2659?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83622 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2659=[""].join("\n");
var outline_f2_38_2659=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H877973627\">",
"      What does it mean when a baby is born premature?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H877973642\">",
"      What causes premature birth?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H877973680\">",
"      What kinds of problems can premature babies have after birth?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H877973695\">",
"      What treatments might my baby need?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H877973710\">",
"      Will my baby have long term problems?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H877973725\">",
"      How can I get support?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H877973740\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83622\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"      Pregnancy terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=related_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/8/29825?source=related_link\">",
"      Patient information: Cerebral palsy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=related_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=related_link\">",
"      Patient information: Having twins (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=related_link\">",
"      Patient information: Jaundice in babies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/29/18897?source=related_link\">",
"      Patient information: Newborn necrotizing enterocolitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/20/27970?source=related_link\">",
"      Patient information: Preterm labor (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/62/23521?source=related_link\">",
"      Patient information: Sepsis in newborn babies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=related_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_38_2660="Bronchiectasis CF PA";
var content_f2_38_2660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchiectasis in cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast bronchogram in a young patient with cystic fibrosis shows fusiform and saccular bronchiectasis in the right lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Julie P Katkin, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2660=[""].join("\n");
var outline_f2_38_2660=null;
var title_f2_38_2661="Congenital esotropia";
var content_f2_38_2661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital esotropia in a three-month-old infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 520px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The right eye is being used for fixation. B) The left eye is being used for fixation. The infant is spontaneously alternating fixation, indicating equal vision in each eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy;2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2661=[""].join("\n");
var outline_f2_38_2661=null;
var title_f2_38_2662="Chloral hydrate: Pediatric drug information";
var content_f2_38_2662=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chloral hydrate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/26/5542?source=see_link\">",
"    see \"Chloral hydrate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33716?source=see_link\">",
"    see \"Chloral hydrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Somnote&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Chloral Hydrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, rectal: 25 mg/kg/dose for sedation prior to a procedure;",
"     <b>",
"      Note:",
"     </b>",
"     Repeat doses should be used with great caution as drug and metabolites accumulate with repeated use; toxicity has been reported after 3 days in a preterm neonate and after 7 days in a term neonate receiving chloral hydrate 40-50 mg/kg every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/26/5542?source=see_link\">",
"      see \"Chloral hydrate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation, anxiety: 25-50 mg/kg/day divided every 6-8 hours, maximum dose: 500 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prior to EEG: 25-50 mg/kg/dose 30-60 minutes prior to EEG; may repeat in 30 minutes to a total maximum of 100 mg/kg or 1 g total for infants and 2 g total for children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation, nonpainful procedure: 50-75 mg/kg/dose 30-60 minutes prior to procedure; may repeat 30 minutes after initial dose if needed, to a total maximum dose of 120 mg/kg or 1 g total for infants and 2 g total for children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypnotic: 50 mg/kg/dose at bedtime; maximum dose: 1 g/dose; total maximum: 1 g/day for infants and 2 g/day for children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation, anxiety: 250 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypnotic: 500-1000 mg at bedtime or 30 minutes prior to procedure, not to exceed 2 g/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Somnote&reg;: 500 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 500 mg/5 mL (5 mL [DSC], 473 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F149289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Minimize unpleasant taste and gastric irritation by administering with water, infant formula, fruit juice, or ginger ale; do not crush capsule, contains drug in liquid form with unpleasant taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal administration: May administer chloral hydrate syrup rectally",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1051640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sensitive to light; exposure to air causes volatilization; store in light-resistant, airtight container at room temperature; do not refrigerate",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term sedative and hypnotic (&lt;2 weeks), sedative/hypnotic prior to nonpainful therapeutic or diagnostic procedures (eg, EEG, CT scan, MRI, ophthalmic exam, dental procedure)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F149293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, disorientation, dizziness, drowsiness, &ldquo;hangover&rdquo; effect, excitement (paradoxical), fever, hallucinations, headache, lightheadedness, nightmares, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, flatulence, gastric irritation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Acute intermittent porphyria, eosinophilia, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Physical and psychological dependence may occur with prolonged use of large doses",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chloral hydrate or any component; hepatic or renal impairment; severe cardiac disease. Oral forms are also contraindicated in patients with gastritis, esophagitis, or gastric or duodenal ulcers.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in neonates, drug and metabolites may accumulate with repeated use; prolonged use in neonates is associated with direct hyperbilirubinemia [active metabolite (TCE) competes with bilirubin for glucuronide conjugation in the liver]; use with caution in patients with porphyria. Tolerance to hypnotic effect develops, therefore, not recommended for use &gt;2 weeks; taper dosage to avoid withdrawal with prolonged use. Avoid use in patients with moderate to severe renal failure (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. Deaths and permanent neurologic injury from respiratory compromise have been reported in children sedated with chloral hydrate; respiratory obstruction may occur in children with tonsillar and adenoidal hypertrophy, obstructive sleep apnea, and Leigh's encephalopathy, and in ASA class III children; depressed levels of consciousness may occur; chloral hydrate should",
"     <b>",
"      not",
"     </b>",
"     be administered for sedation by nonmedical personnel or in a nonsupervised medical environment; sedation with chloral hydrate requires careful patient monitoring (Cote, 2000); animal studies suggest that chloral hydrate may depress the genioglossus muscle and other airway-maintaining muscles in patients who are already at risk for life-threatening airway obstruction (eg, obstructive sleep apnea); alternative sedative agents should be considered for these patients (Hershenson, 1984).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Trichloroethanol (TCE), an active metabolite of chloral hydrate, is a carcinogen in mice; there is no data in humans. Syrup may contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use chloral hydrate products containing sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flumazenil: May diminish the sedative effect of Hypnotics (Nonbenzodiazepine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Furosemide: May enhance the adverse/toxic effect of Chloral Hydrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Hypnotics (Nonbenzodiazepine) may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Chloral Hydrate may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F149236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13447510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Chloral hydrate crosses the placenta and has been found in amniotic fluid and fetal blood.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Level of sedation; vital signs and O",
"     <sub>",
"      2",
"     </sub>",
"     saturation with doses used for sedation prior to procedure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Central nervous system depressant effects are primarily due to its active metabolite trichloroethanol, mechanism unknown; in neonates, chloral hydrate itself may play a role in the immediate sedative effects;",
"     <b>",
"      Note:",
"     </b>",
"     Chloral hydrate does not interfere with EEG results (unlike barbiturates and benzodiazepines)",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, rectal: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses the placenta; distributes to breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Trichloroethanol: 35% to 40%; trichloroacetic acid: &sim;94% (may compete with bilirubin for albumin binding sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly metabolized by alcohol dehydrogenase to trichloroethanol (active metabolite); trichloroethanol undergoes glucuronidation in the liver; variable amounts of chloral hydrate and trichloroethanol are metabolized in liver and kidney to trichloroacetic acid (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloral hydrate: Infants: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trichloroethanol (active metabolite):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: Range: 8.5-66 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Half-life decreases with increasing postmenstrual age (PMA):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Preterm infants (PMA 31-37 weeks): Mean half-life: 40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Term infants (PMA 38-42 weeks): Mean half-life: 28 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Older children (PMA 57-708 weeks): Mean half-life: 10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 8-11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trichloroacetic acid: Adults: 67.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Metabolites excreted in urine; small amounts excreted in feces via bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Dialyzable (50% to 100%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33716?source=see_link\">",
"      see \"Chloral hydrate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; avoid alcohol and other CNS depressants; may be habit-forming; avoid abrupt discontinuation after prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not an analgesic; osmolality of 500 mg/5 mL syrup is approximately 3500 mOsm/kg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Drugs and Committee on Environmental Health, &ldquo;Use of Chloral Hydrate for Sedation in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(3):471-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/38/2662/abstract-text/8361811/pubmed\" id=\"8361811\" target=\"_blank\">",
"        8361811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, &ldquo;Chloral Hydrate Use During Infancy,&rdquo;",
"      <i>",
"       Neonatal Pharmacology Quarterly",
"      </i>",
"      , 1992, 1(1):31-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cote CJ, Karl HW, Notterman DA, et al, &ldquo;Adverse Sedation Events in Pediatrics: Analysis of Medications Used for Sedation,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(4):633-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/38/2662/abstract-text/11015502 /pubmed\" id=\"11015502 \" target=\"_blank\">",
"        11015502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hershenson M, Brouillette RT, Olsen E, et al, &ldquo;The Effect of Chloral Hydrate on Genioglossus and Diaphragmatic Activity,&rdquo;",
"      <i>",
"       Pediatr Res",
"      </i>",
"      , 1984, 18(6):516-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/38/2662/abstract-text/6739190/pubmed\" id=\"6739190\" target=\"_blank\">",
"        6739190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayers DJ, Hindmarsh KW, Gorecki DK, et al, &ldquo;Sedative/Hypnotic Effects of Chloral Hydrate in the Neonate: Trichloroethanol or Parent Drug?&rdquo;",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1992, 19(2-3):141-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/38/2662/abstract-text/1340434/pubmed\" id=\"1340434\" target=\"_blank\">",
"        1340434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayers DJ, Hindmarsh KW, Sankaran K, et al, &ldquo;Chloral Hydrate Disposition Following Single-Dose Administration to Critically Ill Neonates and Children,&rdquo;",
"      <i>",
"       Dev Pharmacol Ther",
"      </i>",
"      , 1991, 16(2):71-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/38/2662/abstract-text/1914781 /pubmed\" id=\"1914781 \" target=\"_blank\">",
"        1914781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steinberg AD, &ldquo;Should Chloral Hydrate be Banned?&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(3)442-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/38/2662/abstract-text/8361800/pubmed\" id=\"8361800\" target=\"_blank\">",
"        8361800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13143 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2662=[""].join("\n");
var outline_f2_38_2662=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149264\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149265\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051645\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442235\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051636\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149241\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149224\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149289\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051650\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051640\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051649\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174520\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149293\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051654\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051635\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051634\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299013\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149233\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149236\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13447510\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051644\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051633\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051652\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051653\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051642\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051655\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13143\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13143|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/26/5542?source=related_link\">",
"      Chloral hydrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33716?source=related_link\">",
"      Chloral hydrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_38_2663="Evaluation of scrotal pain or swelling in children and adolescents";
var content_f2_38_2663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of scrotal pain or swelling in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/38/2663/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2663/contributors\">",
"     Joel S Brenner, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2663/contributors\">",
"     Aderonke Ojo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/38/2663/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2663/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2663/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2663/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/38/2663/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2663/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/38/2663/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of conditions that affect the scrotum and its contents ranges from incidental findings to pathologic events that require expeditious diagnosis and treatment (eg, testicular torsion, testicular cancer). The evaluation of scrotal pain or swelling in children and adolescents will be discussed here. The causes of scrotal pain and swelling are discussed separately, as is the evaluation of the acute scrotum in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link\">",
"     \"Causes of scrotal pain in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link\">",
"     \"Causes of painless scrotal swelling in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44360?source=see_link\">",
"     \"Evaluation of the acute scrotum in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tunica vaginalis and the epididymis are two important landmarks for the testicular examination (",
"    <a class=\"graphic graphic_figure graphicRef75672 \" href=\"UTD.htm?32/1/32786\">",
"     figure 1",
"    </a>",
"    ). The tunica vaginalis is a structure containing a potential space that encompasses the anterior two-thirds of the testicle in which fluid from a variety of sources may accumulate. The epididymis usually is positioned posterolaterally to the testicle and must be differentiated from an abnormal mass. The spermatic cord, which consists of the testicular vessels and the vas deferens, is connected to the base of the epididymis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A focused history in a boy with scrotal pain or swelling can help to narrow the differential diagnosis and lead to a more productive examination. The essential points include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is there history of pain? If so, determine the onset and severity (remember that some adolescents may not report scrotal pain because of modesty or embarrassment) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/38/2663/abstract/1\">",
"       1",
"      </a>",
"      ]. The major causes of acute scrotal pain in children and adolescents are testicular torsion, torsion of testicular or epididymal appendages, and epididymitis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/38/2663/abstract/2\">",
"       2",
"      </a>",
"      ]. These and other causes of testicular and scrotal pain are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link\">",
"       \"Causes of scrotal pain in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is there a history of trauma?",
"     </li>",
"     <li>",
"      Is there a history of change in testicular or scrotal size? If so, what is the onset of this change? Does scrotal size vary with time of day, position, or valsalva maneuver? Such changes are suggestive of communicating hydrocele (with or without an inguinal hernia) or varicocele. These conditions, and other causes of scrotal swelling are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link\">",
"       \"Causes of painless scrotal swelling in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is the patient sexually active? Sexual activity may be associated with epididymitis, although epididymitis also occurs in prepubertal and nonsexually active males. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link&amp;anchor=H13#H13\">",
"       \"Causes of scrotal pain in children and adolescents\", section on 'Epididymitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is the patient having difficulty voiding? Difficulty voiding suggests an intraabdominal, pelvic or rectal mass, urinary tract infection, or neurologic problem, including a lesion of the spinal cord.",
"     </li>",
"     <li>",
"      Is there flank pain or hematuria? These findings suggest a renal stone, which may cause referred pain in the scrotum.",
"     </li>",
"     <li>",
"      Is there abdominal pain associated with decreased appetite, nausea, and vomiting? These findings may be referred pain associated with testicular torsion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parents should receive a brief overview of the genital examination before the examination is begun. A parent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chaperone should be present for the examination if the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    examiner prefers. Uninterrupted privacy must be guaranteed during the examination. The patient's undergarments should be removed, and a gown or towel (held by the patient) should be offered to alleviate any embarrassment.",
"   </p>",
"   <p>",
"    For most aspects of the examination the patient should be standing. The examiner can sit or stand. The evaluation of patients with scrotal pain or swelling should include a detailed examination of the abdomen, inguinal region, and genitalia, including the testes, epididymis, spermatic cord, scrotal skin, penis, and cremasteric reflex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genital examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is to inspect the penis, pubic hair, and inguinal area while the patient is standing. The examiner should notice the presence or absence of any ulcers, papules, urethral discharge, piercings, tattoos, pubic hair infestation, or lymphadenopathy. Ulcers, papules, discharge, and lymphadenopathy may suggest a sexually transmitted infection. Piercings and tattoos may provide a portal of entry for skin and soft tissue infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10282?source=see_link\">",
"     \"Body piercing in adolescents and young adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=see_link&amp;anchor=H11#H11\">",
"     \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'STD clinical patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The position of the testicles (eg, high versus low and horizontal versus vertical) should be evaluated. The left testicle usually lies slightly lower than the right testicle.",
"   </p>",
"   <p>",
"    Patients with varicoceles also should be examined in the supine position. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes of painless scrotal swelling in children and adolescents\", section on 'Varicocele'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examiner should palpate the entire testicular surface by gently rolling it between his or her thumb and forefingers. The testicle should have the consistency of a hard-boiled egg. The epididymis should be palpated in the posterolateral position and followed to the spermatic cord (",
"    <a class=\"graphic graphic_figure graphicRef75672 \" href=\"UTD.htm?32/1/32786\">",
"     figure 1",
"    </a>",
"    ). The examiner should note any swelling or tenderness along any of these structures; if swelling is noted, transillumination may help to determine if it is cystic or solid in nature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link\">",
"     \"Causes of painless scrotal swelling in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cremasteric reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cremasteric reflex should be assessed by stroking the upper thigh while observing the ipsilateral testis. A normal response is cremasteric contraction with elevation of the testis. The reflex is present in the majority of healthy boys between the ages of 30 months and 12 years; it is less consistently present in infants and teenagers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2663/abstract/3\">",
"     3",
"    </a>",
"    ]. The reflex is almost always absent in patients with testicular torsion, which may help to distinguish this condition from other causes of scrotal pain (",
"    <a class=\"graphic graphic_table graphicRef54439 \" href=\"UTD.htm?18/31/18941\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2663/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Prehn sign",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prehn reported that elevation of the scrotal contents relieves the pain in patients with epididymitis and aggravates or has no effect on the pain in patients with testicular torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2663/abstract/5\">",
"     5",
"    </a>",
"    ]. However, Prehn sign is not a reliable distinguishing feature between testicular torsion, epididymitis, and other diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2663/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADDITIONAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal and rectal examinations are indicated if clinical suspicion exists for an abdominal or rectal mass, metastatic visceral disease, or prostatitis. Laboratory and radiologic studies that may be considered include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count (leukocytosis may be present in testicular torsion or epididymitis).",
"     </li>",
"     <li>",
"      Urinalysis and urine culture (pyuria is common in epididymitis but unusual in testicular torsion or torsion of the appendix testis or appendix epididymis).",
"     </li>",
"     <li>",
"      Evaluation for sexually transmitted infections in patients who have findings consistent with sexually transmitted epididymitis. This may include Gram stain, culture, rapid molecular testing, or nucleic acid amplification testing of urethral discharge",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nucleic acid amplification testing of urine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link&amp;anchor=H13#H13\">",
"       \"Causes of scrotal pain in children and adolescents\", section on 'Epididymitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Color Doppler ultrasonography or scintigraphy to assess perfusion and exclude testicular torsion if it cannot be excluded clinically. Ultrasonography is usually preferred to scintigraphy, because it is more readily available and provides more specific visualization of both normal and pathological anatomy.",
"     </li>",
"     <li>",
"      Scrotal exploration is necessary for diagnosis in cases when the clinical examination and imaging cannot exclude testicular torsion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major considerations in the differential diagnosis of scrotal pain or swelling can be divided according to the predominant symptom: pain or swelling. An experienced clinician often can render an accurate diagnosis based upon the history and physical examination alone (",
"    <a class=\"graphic graphic_table graphicRef54439 \" href=\"UTD.htm?18/31/18941\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57879 \" href=\"UTD.htm?16/47/17147\">",
"     table 2",
"    </a>",
"    ). However, advances in color Doppler imaging of the scrotum have made this modality a useful adjunct to the history and physical examination in many cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pain predominant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of acute scrotal pain in children and adolescents are testicular torsion, torsion of the appendix testis, and epididymitis. Other causes include torsion of the appendix epididymis, trauma, Henoch-Sch&ouml;nlein purpura, orchitis, infection (eg, Fournier's gangrene), and referred pain (eg, from a renal stone). Distinguishing clinical features of these conditions are summarized below. Diagnosis and management are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link\">",
"     \"Causes of scrotal pain in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testicular torsion generally presents with the abrupt onset of severe pain [",
"      <a class=\"abstract\" href=\"UTD.htm?2/38/2663/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. The testicle may lie transversely in the scrotum and be retracted",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swollen; the cremasteric reflex typically is absent. Testicular perfusion is decreased and can be assessed on Doppler ultrasound or nuclear scan of the scrotum). Although the clinical and radiographic evaluations may be normal at the time of presentation in a boy with an intermittent torsion that has been reduced, findings may be present to varying degrees on physical examination and imaging. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link&amp;anchor=H2#H2\">",
"       \"Causes of scrotal pain in children and adolescents\", section on 'Testicular torsion'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/44/712?source=see_link\">",
"       \"Neonatal testicular torsion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Torsion of the appendix testis also presents with the abrupt onset of pain, but the pain is generally less severe than in testicular torsion [",
"      <a class=\"abstract\" href=\"UTD.htm?2/38/2663/abstract/1,7,8\">",
"       1,7,8",
"      </a>",
"      ]. The pain is initially localized to the region of the appendix testis (anterosuperior, (",
"      <a class=\"graphic graphic_figure graphicRef67439 \" href=\"UTD.htm?8/60/9152\">",
"       figure 2",
"      </a>",
"      ), although with progression and the development of a reactive hydrocele, diffuse swelling and tenderness may occur. A pathognomic \"blue dot\" sign may be apparent (",
"      <a class=\"graphic graphic_picture graphicRef65781 \" href=\"UTD.htm?38/25/39327\">",
"       picture 1",
"      </a>",
"      ). Testicular perfusion is normal on imaging studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link&amp;anchor=H9#H9\">",
"       \"Causes of scrotal pain in children and adolescents\", section on 'Torsion of the appendix testis or appendix epididymis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epididymitis often presents with a subacute onset of pain and swelling isolated to the epididymis (",
"      <a class=\"graphic graphic_figure graphicRef75672 \" href=\"UTD.htm?32/1/32786\">",
"       figure 1",
"      </a>",
"      ), except in cases of epididymo-orchitis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/38/2663/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. The patient may have a history of frequency, dysuria, urethral discharge,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fever. Testicular perfusion is normal or increased on imaging studies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link&amp;anchor=H13#H13\">",
"       \"Causes of scrotal pain in children and adolescents\", section on 'Epididymitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Incarcerated inguinal hernia usually presents with severe pain and a scrotal or inguinal mass (",
"      <a class=\"graphic graphic_picture graphicRef76424 \" href=\"UTD.htm?35/41/36496\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=see_link\">",
"       \"Overview of inguinal hernia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Scrotal trauma usually is evident from the history. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link&amp;anchor=H18#H18\">",
"       \"Causes of scrotal pain in children and adolescents\", section on 'Trauma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Henoch-Sch&ouml;nlein purpura (HSP) typically is characterized by nonthrombocytopenic purpura, arthralgia, and abdominal pain; however, occasionally scrotal pain may be the only manifestation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Orchitis may be accompanied by systemic manifestations of the underlying infection (eg, brucellosis, mumps, coxsackie, etc).",
"     </li>",
"     <li>",
"      Boys who have the acute onset of scrotal pain without local inflammatory signs or a mass on examination may be suffering from referred pain to the scrotum. The precise incidence of referred pain is unclear. The conditions that may cause referred scrotal pain are diverse and are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link&amp;anchor=H22#H22\">",
"       \"Causes of scrotal pain in children and adolescents\", section on 'Referred pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fournier's gangrene (necrotizing fasciitis of the perineum) is characterized by fulminant destruction of tissue and systemic signs of toxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"       \"Necrotizing soft tissue infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Swelling predominant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of isolated scrotal swelling (as opposed to the generalized edema seen in conditions such as nephrosis) in children and adolescents are hydrocele, varicocele, spermatocele (epididymal cyst), and testicular cancer. Nephrotic syndrome and a number of other conditions producing generalized edema due to hypoproteinemia or increased hydrostatic pressure (eg, protein losing enteropathy, hepatic cirrhosis) also can present with bilateral scrotal swelling. Distinguishing clinical features of hydrocele, varicocele, spermatocele, and testicular cancer are summarized below. Diagnosis and management are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link\">",
"     \"Causes of painless scrotal swelling in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hydrocele is a cystic scrotal fluid collection that transilluminates. A hydrocele that communicates with the peritoneal cavity may increase in size during the day or with the valsalva maneuver. A noncommunicating hydrocele does not change in size or shape with crying or straining. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link&amp;anchor=H2#H2\">",
"       \"Causes of painless scrotal swelling in children and adolescents\", section on 'Hydrocele'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with varicoceles, the spermatic cord has a \"bag of worms\" texture (",
"      <a class=\"graphic graphic_figure graphicRef73206 \" href=\"UTD.htm?7/57/8080\">",
"       figure 3",
"      </a>",
"      ). The varicocele may only be palpable during valsalva maneuver or with standing; varicoceles do not transilluminate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link&amp;anchor=H7#H7\">",
"       \"Causes of painless scrotal swelling in children and adolescents\", section on 'Varicocele'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A spermatocele (epididymal cyst) is a painless, fluid-filled cyst of the head (caput) of the epididymis that may contain nonviable sperm. It transilluminates superior to the testis and can be palpated as distinct from the testis (",
"      <a class=\"graphic graphic_figure graphicRef67291 \" href=\"UTD.htm?26/35/27199\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link&amp;anchor=H10#H10\">",
"       \"Causes of painless scrotal swelling in children and adolescents\", section on 'Spermatocele (epididymal cyst)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testicular cancer usually presents as a painless mass that is firm and does not transilluminate (unless accompanied by a reactive hydrocele). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/29/17873?source=see_link\">",
"       \"Patient information: Hydrocele (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17217?source=see_link\">",
"       \"Patient information: Varicocele (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of scrotal pain and swelling in children and adolescents range from incidental findings to pathologic events that require expeditious diagnosis and treatment (eg, testicular torsion). (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The evaluation should include a focused history, a complete examination with particular attention on the abdomen, inguinal region, and genitalia, including the testes, epididymis, spermatic cord, scrotal skin, penis, and cremasteric reflex. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'History'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Additional evaluation may include a complete blood count, urinalysis and urine culture; Gram stain, culture, rapid molecular testing, and nucleic acid testing of urethral discharge; nucleic acid amplification testing of urine; and Doppler ultrasonography or scintigraphy to assess testicular perfusion. Scrotal exploration is necessary for diagnosis in cases when the clinical examination and imaging cannot exclude testicular torsion. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Additional evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The major considerations in the differential diagnosis of scrotal pain or swelling can be divided according to the predominant symptom.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major causes of scrotal pain in children and adolescents include testicular torsion, testicular appendiceal torsion, and epididymitis (",
"      <a class=\"graphic graphic_table graphicRef54439 \" href=\"UTD.htm?18/31/18941\">",
"       table 1",
"      </a>",
"      ). These conditions are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=see_link\">",
"       \"Causes of scrotal pain in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Major causes of scrotal swelling in children and adolescents include hydrocele, varicocele, spermatocele, and testicular cancer (",
"      <a class=\"graphic graphic_table graphicRef57879 \" href=\"UTD.htm?16/47/17147\">",
"       table 2",
"      </a>",
"      ). These conditions are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=see_link\">",
"       \"Causes of painless scrotal swelling in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2663/abstract/1\">",
"      Petrack EM, Hafeez W. Testicular torsion versus epididymitis: a diagnostic challenge. Pediatr Emerg Care 1992; 8:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2663/abstract/2\">",
"      Lewis AG, Bukowski TP, Jarvis PD, et al. Evaluation of acute scrotum in the emergency department. J Pediatr Surg 1995; 30:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2663/abstract/3\">",
"      Caesar RE, Kaplan GW. The incidence of the cremasteric reflex in normal boys. J Urol 1994; 152:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2663/abstract/4\">",
"      Rabinowitz R. The importance of the cremasteric reflex in acute scrotal swelling in children. J Urol 1984; 132:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2663/abstract/5\">",
"      Edelsberg JS, Surh YS. The acute scrotum. Emerg Med Clin North Am 1988; 6:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2663/abstract/6\">",
"      Haynes BE, Bessen HA, Haynes VE. The diagnosis of testicular torsion. JAMA 1983; 249:2522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2663/abstract/7\">",
"      Pillai SB, Besner GE. Pediatric testicular problems. Pediatr Clin North Am 1998; 45:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2663/abstract/8\">",
"      Kass EJ, Lundak B. The acute scrotum. Pediatr Clin North Am 1997; 44:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2663/abstract/9\">",
"      Kadish HA, Bolte RG. A retrospective review of pediatric patients with epididymitis, testicular torsion, and torsion of testicular appendages. Pediatrics 1998; 102:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2663/abstract/10\">",
"      Karmazyn B, Steinberg R, Kornreich L, et al. Clinical and sonographic criteria of acute scrotum in children: a retrospective study of 172 boys. Pediatr Radiol 2005; 35:302.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6449 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2663=[""].join("\n");
var outline_f2_38_2663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genital examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Inspection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cremasteric reflex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Prehn sign",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADDITIONAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pain predominant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Swelling predominant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6449\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6449|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/1/32786\" title=\"figure 1\">",
"      Scrotal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/60/9152\" title=\"figure 2\">",
"      Testicular appendages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/57/8080\" title=\"figure 3\">",
"      Varicocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/35/27199\" title=\"figure 4\">",
"      Spermatocele",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6449|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/25/39327\" title=\"picture 1\">",
"      Appendix testis torsion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/41/36496\" title=\"picture 2\">",
"      Strangulated hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6449|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/31/18941\" title=\"table 1\">",
"      Differential diagnosis of pediatric scrotal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/47/17147\" title=\"table 2\">",
"      Differential diagnosis painless scrotal mass",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10282?source=related_link\">",
"      Body piercing in adolescents and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43766?source=related_link\">",
"      Causes of painless scrotal swelling in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/39/32376?source=related_link\">",
"      Causes of scrotal pain in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44360?source=related_link\">",
"      Evaluation of the acute scrotum in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/44/712?source=related_link\">",
"      Neonatal testicular torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/3/21561?source=related_link\">",
"      Overview of inguinal hernia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/29/17873?source=related_link\">",
"      Patient information: Hydrocele (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17217?source=related_link\">",
"      Patient information: Varicocele (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37689?source=related_link\">",
"      Sexually transmitted diseases: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_38_2664="Fasciolopsiasis life cycle";
var content_f2_38_2664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65448&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Fasciolopsiasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 477px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immature eggs are discharged into the intestine and stool",
"    <strong>",
"     (1)",
"    </strong>",
"    . Eggs become embryonated in water",
"    <strong>",
"     (2)",
"    </strong>",
"    , eggs release miracidia",
"    <strong>",
"     (3)",
"    </strong>",
"    , which invade a suitable snail intermediate host",
"    <strong>",
"     (4)",
"    </strong>",
"    . In the snail, the parasites undergo several developmental stages (sporocysts",
"    <strong>",
"     (4a)",
"    </strong>",
"    , rediae",
"    <strong>",
"     (4b)",
"    </strong>",
"    , and cercariae",
"    <strong>",
"     (4c)",
"    </strong>",
"    ). The cercariae are released from the snail",
"    <strong>",
"     (5)",
"    </strong>",
"    and encyst as metacercariae on aquatic plants",
"    <strong>",
"     (6)",
"    </strong>",
"    . The mammalian hosts become infected by ingesting metacercariae on the aquatic plants. After ingestion, the metacercariae excyst in the duodenum",
"    <strong>",
"     (7)",
"    </strong>",
"    and attach to the intestinal wall. There they develop into adult flukes (20 to 75 mm by 8 to 20 mm) in approximately three months, attached to the intestinal wall of the mammalian hosts (humans and pigs)",
"    <strong>",
"     (8)",
"    </strong>",
"    . The adults have a life span of about one year.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Fasciolopsiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Fasciolopsiasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Fasciolopsiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2664=[""].join("\n");
var outline_f2_38_2664=null;
var title_f2_38_2665="Pharmacotherapy for generalized anxiety disorder";
var content_f2_38_2665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacotherapy for generalized anxiety disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/38/2665/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2665/contributors\">",
"     Alexander Bystritsky, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/38/2665/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2665/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/38/2665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2665/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/38/2665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H72104624\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized anxiety disorder (GAD) is characterized by excessive worry and anxiety that are difficult to control, cause significant distress and impairment, and occur on more days than not for at least six months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generalized anxiety disorder (GAD) is a relatively common disorder, most often with onset during adulthood and a chronic course [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. GAD can lead to significant impairments in role functioning, diminished quality of life, and high health care costs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The disorder can be effectively treated with medication, psychotherapy, or a combination of the two modalities.",
"   </p>",
"   <p>",
"    This topic will address pharmacotherapy for GAD. The epidemiology, pathogenesis, clinical manifestations, course, diagnosis, and treatment of GAD with psychotherapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=see_link\">",
"     \"Psychotherapy for generalized anxiety disorder\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1639259\">",
"    <span class=\"h1\">",
"     FIRST-LINE MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line medications for GAD are selective-serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425713266\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRIs that have been shown in randomized trials to be efficacious for GAD include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/8-10\">",
"     8-10",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/11,12\">",
"     11,12",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Uncontrolled trials and our clinical experience suggest other SSRIs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    ) are effective for GAD as well. A systematic review concluded that five patients with GAD would need to be treated with antidepressants (rather than placebo) for one patient to achieve a clinical response (ie, NNT = 5) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, the largest trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    at two fixed doses (20 and 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    to placebo in 566 patients with generalized anxiety disorder. After eight weeks of treatment, both doses of paroxetine resulted in a greater reduction of anxiety symptoms than placebo (62 and 68 percent versus 46 percent, respectively). Rates of remission (defined as &le;7 on the Hamilton Rating Scale for Anxiety) followed the same pattern: 30 and 36 percent for patients receiving 20 and 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of paroxetine groups, respectively, compared to 20 percent for patients receiving placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/9\">",
"     9",
"    </a>",
"    ]. Randomized trials have shown SSRIs maintain efficacy for at least six months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/17\">",
"     17",
"    </a>",
"    ]. Our clinical experience has been that they work for a much longer time in this chronic condition.",
"   </p>",
"   <p>",
"    There is a paucity of data available that directly compares different SSRIs for GAD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Trials have generally shown that all SSRIs studied have the same degree of effectiveness, ie, response rates of approximately 60 to 70 percent for the SSRI, versus 40 percent for the placebo. Consequently, selecting which SSRI to administer is guided more by side effect profile than by published reports of efficacy. A table compares efficacy, advantages, and disadvantages of antidepressants for GAD (",
"    <a class=\"graphic graphic_table graphicRef77409 \" href=\"UTD.htm?19/15/19710\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    SSRIs can produce side effects that interfere with the patient&rsquo;s quality of life and medication adherence. Thus, side effects need to be recognized and managed early in treatment. Individual SSRIs vary in their side effect profile, but common side effects include sexual dysfunction, gastrointestinal abnormalities (nausea and diarrhea), insomnia and withdrawal on discontinuation. SSRIs can cause drug interactions, weight gain, and agitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperactivation. A table compares side effects of antidepressants (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 2",
"    </a>",
"    ). Management of SSRI side effects is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=see_link\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic doses of SSRIs are approximately the same as for the treatment of depression. Starting doses from the lower end of the recommended range should be used to avoid initial agitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Time to onset of clinically meaningful action for an SSRI varies by patient, but averages approximately four weeks. A concomitantly administered benzodiazepine (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    1 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses) can be used to treat agitation and anxiety during this time. After four weeks, if a patient has shown a partial response, the dose can be slowly increased. If the patient has not shown any signs of improvement after six to eight weeks on a therapeutic dose, the medication should be tapered off and another medication should be tried.",
"   </p>",
"   <p>",
"    As an example, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    can be initiated at 5 to 10 mg and increased to 20 mg for an initial trial. Dose increases (up to 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    should be done slowly, eg, once weekly in 10 mg increments. When discontinued, SSRIs should be tapered off gradually.",
"   </p>",
"   <p>",
"    In cases of co-occurring GAD and depression, a common comorbidity, SSRIs can provide effective treatment for both GAD and major depression. Other anxiolytics, such as benzodiazepines, are not effective monotherapies for depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If treatment with an SSRI is not effective, typically a second trial with a different SSRI would precede a switch to use of a second-line medication or augmentation of the initial SSRI. A stepped-care algorithm for GAD pharmacotherapy provides more detailed information. (See",
"    <a class=\"local\" href=\"#H870655\">",
"     'Algorithm for stepped pharmacotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450954836\">",
"    <span class=\"h2\">",
"     Serotonin&ndash;norepinephrine reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serotonin&ndash;norepinephrine reuptake inhibitors (SNRIs) inhibit serotonin and norepinephrine reuptake. Their use follows the same general guidelines as SSRI treatment.",
"   </p>",
"   <p>",
"    SNRIs are comparable to SSRIs in efficacy and tolerability for GAD. We favor use of an SSRI primarily because SNRIs are not yet available in generic form in the United States. (Immediate-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    is available, but this formulation can cause greater side effects.) SNRIs can be used instead of SSRIs if preferred based on their side effect profile, drug-to-drug interactions, or patient treatment history or preference.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    (extended release [ER]) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/20-22\">",
"     20-22",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/23,24\">",
"     23,24",
"    </a>",
"    ] have been shown to be efficacious in randomized trials. As an example, venlafaxine ER at three fixed doses (37.5, 75, and 150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    has been compared to placebo in a randomized trial of 541 outpatients with GAD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/25\">",
"     25",
"    </a>",
"    ]. The two higher doses (75 and 150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    demonstrated greater efficacy than placebo on all primary outcome measures at 8 and 24 weeks, while the lower dose (37.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    did not. Longer-term trials have demonstrated efficacy for as long as six months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. Both medications have been approved by the Food and Drug Administration (FDA) in the United States (US) for GAD.",
"   </p>",
"   <p>",
"    Common side effects of SNRIs&nbsp;are nausea, dizziness, insomnia, sedation, constipation, and sweating.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    &nbsp;may increase blood pressure, usually to a small extent. Rates of 3 to 7 percent have been seen at doses of 100 to 300",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    while the incidence of increased blood pressure was 13 percent at daily doses &gt;300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/27\">",
"     27",
"    </a>",
"    ]. Typically, we ask patients with doses of venlafaxine of 150 mg per day or higher to monitor their blood pressure. If blood pressure is increased in most cases, we either add or modify antihypertensive treatment. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21481843\">",
"    <span class=\"h1\">",
"     SECOND-LINE MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-line medications for GAD include tricyclic antidepressants, benzodiazepines, and certain anti-convulsants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72104725\">",
"    <span class=\"h2\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"     Imipramine",
"    </a>",
"    , a tricyclic antidepressant (TCA), has been shown to be efficacious in treatment of patients with GAD, including those without comorbid depression or panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/16\">",
"     16",
"    </a>",
"    ]. However, SSRIs and SNRIs are generally preferred over TCAs because the latter have an increased risk of cardiotoxicity in overdose and less acceptable tolerability profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72104732\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines have been found to be efficacious in the treatment of GAD, generally leading to a reduction of emotional and somatic symptoms within minutes to hours, depending on the specific medication (",
"    <a class=\"graphic graphic_table graphicRef65653 \" href=\"UTD.htm?39/16/40205\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/29\">",
"     29",
"    </a>",
"    ]. However, concerns about risks of dependence and tolerance have contributed to a decline in their use [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/8,21\">",
"     8,21",
"    </a>",
"    ]. A large observational study of treatment of US patients with GAD (without comorbidity) found that between 1989 to 1991 and 1996 benzodiazepine use declined and antidepressant use increased [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While benzodiazepines should be used with caution, their use need not be entirely avoided. They may be appropriate during acute, maintenance, or long-term treatment of GAD, either as monotherapy or, more commonly, as an adjunct to antidepressant treatment. Benzodiazepines are most commonly used in GAD for acute management of anxiety and worry during the period before SSRIs or SNRIs take effect. They can counteract the initial agitation often caused by the SSRI. This approach may be helpful for patients who cannot tolerate the initial activating effects of SSRIs for GAD. Once the patient responds to the SSRI, the benzodiazepine can be tapered off gradually. Antidepressants are preferred over benzodiazepines when depression, a common comorbidity of GAD, is also present, because antidepressants are effective treatments for both conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with chronic GAD, minimal current depressive symptoms, and no history of substance abuse are candidates for long-term, low-dose benzodiazepine treatment if antidepressants are ineffective or poorly tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/31\">",
"     31",
"    </a>",
"    ]. &nbsp;Some patients respond well to chronic treatment with benzodiazepines, do not develop tolerance to their anxiolytic effects, which would require dose increase and experience only mild, tolerable withdrawal symptoms when the medication is tapered off. Patients who develop rapid tolerance, increase their doses against medical advice, or exhibit withdrawal symptoms between doses are not good candidates for chronic benzodiazepine treatment.",
"   </p>",
"   <p>",
"    Side effects of benzodiazepines include impairment of psychomotor performance, amnesia, dependence and withdrawal symptoms after long-term treatment, and rebound anxiety after short-term treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/32\">",
"     32",
"    </a>",
"    ]. Withdrawal and cognitive or learning impairment are more likely for persons taking higher doses.",
"   </p>",
"   <p>",
"    As examples, benzodiazepine treatment can be started with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    at 0.25 to 0.5 mg orally once or twice daily and titrated up to 1 mg two or three times daily as needed based on response.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    is also a suitable choice, starting at 2.5 to 5 mg orally once or twice daily and titrated up to 10 mg two or three times daily based on response.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    , a benzodiazepine with an intermediate onset of action and shorter half-life can be started&nbsp;at 0.5 to 1 mg orally three times daily and titrated up to 1.5 mg four times daily as needed based on response.",
"   </p>",
"   <p>",
"    Tapering off benzodiazepines is usually done very slowly, at approximately a 10 percent dose reduction per one to two weeks, if circumstances allow. The prescriber should monitor the patient for symptoms of benzodiazepine withdrawal or relapse of GAD and slow the rate of dose reduction accordingly. Early signs of benzodiazepine withdrawal include anxiety, dysphoria, and tremor; advanced manifestations include perceptual disturbances, psychosis, and seizures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link\">",
"     \"Benzodiazepine poisoning and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the antidepressants discussed above, which are thought to exert their primary effect via either the serotonergic or noradrenergic system or both, the benzodiazepines act mostly via gamma-aminobutyric acid (GABA). Generally, benzodiazepines have a faster onset of action than antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450954525\">",
"    <span class=\"h2\">",
"     Buspirone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The azapirone",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    has been shown in several randomized trials to reduce symptoms of anxiety in patients with GAD, offering similar efficacy to the benzodiazepine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    without the risk of dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/34\">",
"     34",
"    </a>",
"    ]. Buspirone&rsquo;s FDA approval for &ldquo;anxiety disorders&rdquo; preceded the tendency of FDA to assign indications according to specific psychiatric disorders, but it is generally considered to apply to the diagnosis of GAD. Buspirone is thought to affect the serotonergic",
"    <strong>",
"    </strong>",
"    system via blockade of 5HT1A autoreceptors.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     Buspirone",
"    </a>",
"    &rsquo;s time to onset is longer than the benzodiazepines&rsquo; and similar to the antidepressants&rsquo; average of four weeks. In our experience, it has a weaker anxiolytic effect than benzodiazepines. These factors have limited its use by psychiatrists largely to augmentation of SSRIs for GAD, though it remains a popular treatment for GAD among primary care practitioners. Buspirone can be used as monotherapy (in the absence of comorbid major depression) or for augmentation at doses of 10 to 60",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72104753\">",
"    <span class=\"h2\">",
"     Pregabalin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    is sometimes used to treat GAD. Pregabalin inhibits calcium currents via high-voltage-activated channels containing the a2d-1 subunit, though the relationship of this mechanism to its efficacy in GAD is not known. Pregabalin has shown efficacy for GAD compared to placebo in several randomized trials. It has recently been approved for the treatment of anxiety in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Pregabalin is not approved for treating GAD by the US FDA. The doses for pregabalin range from 50 to 300 mg. Side effects include sedation and dizziness. Tolerance, withdrawal and dependence are possible, but pregabalin is generally better tolerated than benzodiazepines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72105014\">",
"    <span class=\"h1\">",
"     OTHER MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 40 percent of GAD patients fail to improve or have residual symptoms in response to multiple trials of first and second-line medications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/8,21\">",
"     8,21",
"    </a>",
"    ]. Thus, a number of medications have been used as monotherapy or augmenting agents for treatment-resistant GAD despite variable levels of supporting evidence. These include other antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    , and atypical antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72104769\">",
"    <span class=\"h2\">",
"     Other antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    , as a single agent or as augmentation to an SSRI, may be useful in the treatment of refractory anxiety with insomnia. Sedation and weight gain are two prominent side effects of this agent. Clinical trials on the use of mirtazapine in GAD are insufficient to determine efficacy; the US FDA has not approved mirtazapine for GAD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72104790\">",
"    <span class=\"h2\">",
"     Antipsychotic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another potential pharmacological treatment strategy for treatment resistant GAD involves the use of second-generation antipsychotic medication. Several randomized clinical trials support the use of atypical neuroleptics in GAD, either as part of an augmentation strategy or as single agents [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/39\">",
"     39",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    has been used for GAD, but has not been approved for the disorder by the US FDA.",
"   </p>",
"   <p>",
"    Adverse side effects associated with second generation antipsychotics include sedation, extrapyramidal symptoms, and tardive dyskinesia (TD) (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"UTD.htm?37/46/38639\">",
"     table 2",
"    </a>",
"    ). Although rare, TD may persist indefinitely. Other side effects associated mainly with second-generation antipsychotics include weight gain and elevation of glucose and lipid levels. Because of the likelihood of these types of adverse effects, atypical antipsychotics should be considered (usually adjunctively to an SSRI or SNRI) for treatment resistant GAD after safer alternatives have been exhausted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27269?source=see_link\">",
"     \"Tardive dyskinesia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29190879\">",
"    <span class=\"h2\">",
"     Tiagabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=see_link\">",
"     Tiagabine",
"    </a>",
"    has not been found to be superior to placebo for GAD in three randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72104797\">",
"    <span class=\"h2\">",
"     Hydroxyzine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of five trials with 884 patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    appeared efficacious for GAD, though the analysis suggested a high risk of bias [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/41\">",
"     41",
"    </a>",
"    ]. Hydroxyzine was found to be more sedating than benzodiazepines and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    , and thus potentially useful for treating insomnia associated with GAD. Other medications that have sedative effects could be used for this purpose, eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"     eszopiclone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/42\">",
"     42",
"    </a>",
"    ], though this has not been well studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H425712691\">",
"    <span class=\"h1\">",
"     COMPLEMENTARY AND ALTERNATIVE TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many people suffering from GAD and other anxiety disorders turn to herbal medicines and food supplements to treat their condition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/43\">",
"     43",
"    </a>",
"    ]. &nbsp;Some patients prefer herbal remedies because they perceive them to be safer than prescribed psychotropic medication. However, these remedies can pose serious risks and must be used cautiously [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kava-kava, valerian root and passion flower have been used in the treatment of anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/45\">",
"     45",
"    </a>",
"    ]. However, there are no adequate randomized trials of these agents in GAD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/46\">",
"     46",
"    </a>",
"    ]. Kava-Kava has been linked to acute liver failure and was temporarily taken off the market [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/47\">",
"     47",
"    </a>",
"    ]. Herbal remedies have been also associated with significant drug interactions.",
"   </p>",
"   <p>",
"    Acupuncture for GAD has been studied in several randomized trials; however, methodologic problems limit the conclusions that can be drawn from these reports [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary evidence suggests that exercise reduces anxiety sensitivity and may reduce generalized anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/49\">",
"     49",
"    </a>",
"    ]. The clinical implications of these limited data are yet to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604266454\">",
"    <span class=\"h1\">",
"     DURATION OF PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If effective, antidepressant treatment for GAD should be continued for at least 12 months rather than the six months supported by previous research [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/50\">",
"     50",
"    </a>",
"    ]. In a randomized trial, 136 patients with GAD who experienced reduced anxiety during six months of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    XR were assigned to continue the medication or to placebo for an additional six months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients continuing venlafaxine XR had a much lower rate of relapse during the second six months than patients receiving placebo (9.8 versus 53.7 percent). Incidence rates of side effects during the second six months compared to the first six months were lower, did not differ statistically",
"    <sup>",
"    </sup>",
"    between drug and placebo patients, and included no new side effects.",
"   </p>",
"   <p>",
"    If the patient experiences a relapse following termination of an effective medication, the length of treatment can be extended. After two relapses when tapering off the medication, ongoing maintenance treatment should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H870655\">",
"    <span class=\"h1\">",
"     ALGORITHM FOR STEPPED PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A figure outlines a stepped approach to pharmacotherapy for GAD (",
"    <a class=\"graphic graphic_algorithm graphicRef64594 \" href=\"UTD.htm?13/31/13808\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Step 1 &mdash; Would typically start with a selective serotonin reuptake inhibitor (SSRI) antidepressant. SSRIs can provide effective treatment for both GAD and major depression, a common comorbid disorder. (See",
"      <a class=\"local\" href=\"#H1639259\">",
"       'First-line medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Step 2",
"      <strong>",
"      </strong>",
"      &mdash; Nonresponse after an adequate SSRI trial can be followed by a different SSRI, followed by a trial of a serotonergic-noradrenergic reuptake inhibitor (SNRI) or tricyclic antidepressant. A partial response to the initial antidepressant can be followed with augmentation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      , or (if insomnia)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H21481843\">",
"       'Second-line medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Step 3 &mdash; Nonresponse after an adequate trials of second-line antidepressants can be followed by trials of other less well studied antidepressants. Partial response can be addressed by augmentation. (See",
"      <a class=\"local\" href=\"#H72105014\">",
"       'Other medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3471601\">",
"    <span class=\"h1\">",
"     COMPARING MEDICATION TO CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is insufficient evidence directly comparing the effectiveness of medication for GAD to cognitive behavioral therapy (CBT), the best studied and most effective psychotherapy for GAD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Meta-analyses comparing the effect sizes of the two modalities have found largely equivalent results [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/54\">",
"     54",
"    </a>",
"    ].We suggest that the choice between them should be based on treatment availability and patient preference. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=see_link\">",
"     \"Psychotherapy for generalized anxiety disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H211197366\">",
"    <span class=\"h1\">",
"     COMBINED MEDICATION AND CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two trials have found the combination of a benzodiazepine and CBT to be more effective for GAD than a benzodiazepine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Another trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    , CBT or the combination in 448 7 to 17 year olds with separation anxiety, generalized anxiety, or social phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2665/abstract/57\">",
"     57",
"    </a>",
"    ], finding that the combination treatment was superior to either monotherapy, with all three treatment groups showing greater reduction in anxiety compared to placebo. The number of adverse events, including suicidal and homicidal ideation, did not differ across the groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=see_link&amp;anchor=H15673212#H15673212\">",
"     \"Psychotherapy for generalized anxiety disorder\", section on 'Cognitive behavioral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While they can be beneficial, treatment that integrates medication with CBT should be administered with caution to avoid counterproductive interactions. As an example, benzodiazepines and, to a lesser degree, sedating SSRIs can disrupt the learning of new coping strategies, a mechanism that is fundamental to CBT. Several principals should guide combined treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stabilization of medications prior to starting CBT",
"     </li>",
"     <li>",
"      Avoidance of &ldquo;as needed&rdquo; or large doses of benzodiazepines",
"     </li>",
"     <li>",
"      Avoidance of other medications that have sedative effects (eg, sedative SSRIs) while CBT is in progress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/32/32257?source=see_link\">",
"       \"Patient information: Generalized anxiety disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1639447\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend first-line treatment of generalized anxiety disorder (GAD) with either a serotonergic antidepressant or cognitive behavioral therapy (CBT) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Both interventions have been found to be efficacious in randomized trials compared to placebo. There has been little study comparing the two modalities (See",
"      <a class=\"local\" href=\"#H3471601\">",
"       'Comparing medication to CBT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=see_link\">",
"       \"Psychotherapy for generalized anxiety disorder\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When medication is used to treat GAD, we recommend selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) as first-line medication treatment (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). In cases of co-occurring GAD and depression, a common comorbidity, SSRIs, or SNRIs can provide effective treatment for both disorders. (See",
"      <a class=\"local\" href=\"#H1639259\">",
"       'First-line medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Randomized trials have established the efficacy of the serotonergic antidepressants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      extended release, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      . In our clinical experience, the other SSRIs or SNRIs are also effective treatments for GAD.",
"     </li>",
"     <li>",
"      As an example, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      can be initiated at 5 to 10 mg and increased to 20 mg for an initial trial. Dose increases (up to 40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      should be done slowly, eg, once weekly in 10 mg increments.",
"     </li>",
"     <li>",
"      Extended release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      has been shown to be effective at 75 and 150",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      in doses 20 to 90 mg per day.",
"     </li>",
"     <li>",
"      If effective, we recommend continuing SSRI or SNRI therapy in the treatment of generalized anxiety disorder for at least 12 months rather than the 6 months supported by previous research (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H604266454\">",
"       'Duration of pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Second-line medications for GAD that is nonresponsive to SSRIs and SNRIs include tricyclic antidepressants (TCAs), benzodiazepines, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Benzodiazepines are effective for acute and long-term treatment of GAD, but should generally be reserved for patients without a history of substance abuse. They may also be useful for acute symptoms during the period before an SSRI takes effect, or as an adjunct for partial responders to SSRIs or SNRIs. As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      can be started at 0.25 to 0.5 mg orally one or two times daily and titrated up to 1 mg two or three times daily based on response. (See",
"      <a class=\"local\" href=\"#H72104732\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       Pregabalin",
"      </a>",
"      has shown efficacy for GAD in several randomized trials",
"      <strong>",
"      </strong>",
"      in doses from 50 to 300 mg per day. (See",
"      <a class=\"local\" href=\"#H72104753\">",
"       'Pregabalin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other interventions used for treatment-resistant GAD, either as monotherapy or in augmentation of SSRIs, include CBT,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H72105014\">",
"       'Other medications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H211197366\">",
"       'Combined medication and CBT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=see_link\">",
"       \"Psychotherapy for generalized anxiety disorder\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/2\">",
"      Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005; 15:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/3\">",
"      Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/4\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/5\">",
"      Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005; 162:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/6\">",
"      Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/7\">",
"      Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin Ther 2009; 31:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/8\">",
"      Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. Int Clin Psychopharmacol 2000; 15:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/9\">",
"      Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/10\">",
"      Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003; 64:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/11\">",
"      Brawman-Mintzer O, Knapp RG, Rynn M, et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/12\">",
"      Dahl AA, Ravindran A, Allgulander C, et al. Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Acta Psychiatr Scand 2005; 111:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/13\">",
"      Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/14\">",
"      Davidson JR, Bose A, Wang Q. Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2005; 66:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/15\">",
"      Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005; 87:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/16\">",
"      Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003; :CD003592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/17\">",
"      Rickels K, Rynn M, Iyengar M, Duff D. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 2006; 67:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/18\">",
"      Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/19\">",
"      Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/20\">",
"      Lydiard RB. An overview of generalized anxiety disorder: disease state--appropriate therapy. Clin Ther 2000; 22 Suppl A:A3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/21\">",
"      Allgulander C, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003; 8:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/22\">",
"      Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of Generalized Anxiety Disorder. Int J Neuropsychopharmacol 2005; 8:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/23\">",
"      Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 2009; 23:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/24\">",
"      Carter CS, Krug MK. The functional neuroanatomy of dread: Functional magnetic resonance imaging insights into generalized anxiety disorder and its treatment. Am J Psychiatry 2009; 166:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/25\">",
"      Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/26\">",
"      Stahl SM, Ahmed S, Haudiquet V. Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. CNS Spectr 2007; 12:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/27\">",
"      Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatry 1997; 9:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/28\">",
"      Keller MB. The long-term clinical course of generalized anxiety disorder. J Clin Psychiatry 2002; 63 Suppl 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/29\">",
"      Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001; 62 Suppl 11:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/30\">",
"      Salzman C, Goldenberg I, Bruce SE, Keller MB. Pharmacologic treatment of anxiety disorders in 1989 versus 1996: results from the Harvard/Brown anxiety disorders research program. J Clin Psychiatry 2001; 62:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/31\">",
"      Pollack MH. Refractory generalized anxiety disorder. J Clin Psychiatry 2009; 70 Suppl 2:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/32\">",
"      Rickels K, Lucki I, Schweizer E, et al. Psychomotor performance of long-term benzodiazepine users before, during, and after benzodiazepine discontinuation. J Clin Psychopharmacol 1999; 19:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/33\">",
"      Brawman-Mintzer O. Pharmacologic treatment of generalized anxiety disorder. Psychiatr Clin North Am 2001; 24:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/34\">",
"      Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; :CD006115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/35\">",
"      Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010; 13:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/36\">",
"      Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007; 27:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/37\">",
"      Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry 2006; 11:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/38\">",
"      Schatzberg AF. New indications for antidepressants. J Clin Psychiatry 2000; 61 Suppl 11:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/39\">",
"      Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 2006; 67:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/40\">",
"      Pollack MH, Tiller J, Xie F, Trivedi MH. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008; 28:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/41\">",
"      Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev 2010; :CD006815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/42\">",
"      Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008; 65:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/43\">",
"      Roy-Byrne PP, Bystritsky A, Russo J, et al. Use of herbal medicine in primary care patients with mood and anxiety disorders. Psychosomatics 2005; 46:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/44\">",
"      Bressler R. Herb-drug interactions: interactions between kava and prescription medications. Geriatrics 2005; 60:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/45\">",
"      Sarris J, Kavanagh DJ. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med 2009; 15:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/46\">",
"      Lakhan SE, Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J 2010; 9:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/47\">",
"      Whitton PA, Lau A, Salisbury A, et al. Kava lactones and the kava-kava controversy. Phytochemistry 2003; 64:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/48\">",
"      Pilkington K, Kirkwood G, Rampes H, et al. Acupuncture for anxiety and anxiety disorders--a systematic literature review. Acupunct Med 2007; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/49\">",
"      Broman-Fulks JJ, Berman ME, Rabian BA, Webster MJ. Effects of aerobic exercise on anxiety sensitivity. Behav Res Ther 2004; 42:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/50\">",
"      Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 2000; 283:3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/51\">",
"      Rickels K, Etemad B, Khalid-Khan S, et al. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry 2010; 67:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/52\">",
"      Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev 2007; :CD001848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/53\">",
"      Hendriks GJ, Oude Voshaar RC, Keijsers GP, et al. Cognitive-behavioural therapy for late-life anxiety disorders: a systematic review and meta-analysis. Acta Psychiatr Scand 2008; 117:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/54\">",
"      Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol Bull 2005; 131:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/55\">",
"      Power KG, Simpson RJ, Swanson V, Wallace LA. A controlled comparison of cognitive-behaviour therapy, diazepam, and placebo, alone and in combination, for the treatment of generalised anxiety disorder. J Anxiety Disord 1990; 4:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/56\">",
"      Power KG, Simpson RJ, Swanson V, Wallace LA. Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. Br J Gen Pract 1990; 40:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2665/abstract/57\">",
"      Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359:2753.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14631 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-103.10.120.51-1F944A4537-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2665=[""].join("\n");
var outline_f2_38_2665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1639447\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72104624\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1639259\">",
"      FIRST-LINE MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H425713266\">",
"      Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450954836\">",
"      Serotonin&ndash;norepinephrine reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21481843\">",
"      SECOND-LINE MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72104725\">",
"      Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72104732\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450954525\">",
"      Buspirone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72104753\">",
"      Pregabalin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72105014\">",
"      OTHER MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72104769\">",
"      Other antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72104790\">",
"      Antipsychotic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29190879\">",
"      Tiagabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72104797\">",
"      Hydroxyzine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H425712691\">",
"      COMPLEMENTARY AND ALTERNATIVE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H604266454\">",
"      DURATION OF PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H870655\">",
"      ALGORITHM FOR STEPPED PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3471601\">",
"      COMPARING MEDICATION TO CBT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H211197366\">",
"      COMBINED MEDICATION AND CBT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1639447\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14631\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14631|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?13/31/13808\" title=\"algorithm 1\">",
"      Stepped pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14631|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/15/19710\" title=\"table 1\">",
"      Antidepressants for treatment of generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/46/38639\" title=\"table 2\">",
"      Side effects antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/16/40205\" title=\"table 3\">",
"      Pharmacology benzodiazepines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/32/32257?source=related_link\">",
"      Patient information: Generalized anxiety disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=related_link\">",
"      Psychotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=related_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27269?source=related_link\">",
"      Tardive dyskinesia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_38_2666="Treatment and prevention of streptococcal tonsillopharyngitis";
var content_f2_38_2666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of streptococcal tonsillopharyngitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/38/2666/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2666/contributors\">",
"     Michael E Pichichero, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/38/2666/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2666/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2666/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/38/2666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/38/2666/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/38/2666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group A streptococcal (GAS) tonsillopharyngitis presents with abrupt onset of sore throat, tonsillar exudate, tender cervical adenopathy, and fever, followed by spontaneous resolution within two to five days. Patients with sore throat lasting longer than one week usually do not have GAS tonsillopharyngitis.",
"   </p>",
"   <p>",
"    Issues related to treatment and prevention of group A streptococcal tonsillopharyngitis will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/1\">",
"     1",
"    </a>",
"    ]. A general approach to patients with pharyngitis and the factors responsible for antibiotic failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link\">",
"     \"Evaluation of acute pharyngitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6758?source=see_link\">",
"     \"Antibiotic failure in the treatment of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goals of antimicrobial therapy for eradication of GAS from the pharynx in the setting of acute streptococcal pharyngitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reducing duration and severity of clinical signs and symptoms, including suppurative complications",
"     </li>",
"     <li>",
"      Reducing incidence of nonsuppurative complications (eg, acute rheumatic fever)",
"     </li>",
"     <li>",
"      Reducing transmission to close contacts by reducing infectivity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Considerations of treatment include ease of antibiotic administration and limited expense with as few adverse effects as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Reducing clinical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy is most beneficial for hastening resolution of symptoms if instituted within the first two days of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Antibiotic therapy is also beneficial for reducing suppurative complications such as peritonsillar abscess, cervical lymphadenitis, and mastoiditis. Additional issues related to antibiotic therapy for reducing clinical symptoms are discussed further below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Timing of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reducing nonsuppurative complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy is primarily helpful for reducing the incidence of acute rheumatic fever as a nonsuppurative complication of GAS pharyngitis. The role of antibiotic therapy in decreasing the nonsuppurative complications of glomerulonephritis and PANDAS syndrome is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Acute rheumatic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although symptoms of GAS pharyngitis resolve without antibiotic therapy, persistence of the organism in the upper respiratory tract elicits an immune response that can set the stage for subsequent risk of acute rheumatic fever (ARF) if the strain is rheumatogenic and the host is genetically predisposed. In some populations, group G and group C streptococci may also play a role in ARF pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=see_link\">",
"     \"Epidemiology and pathogenesis of acute rheumatic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\", section on 'Predisposing factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of penicillin for primary prevention of ARF was established in the early 1950s, when military recruits with GAS tonsillopharyngitis received injectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    mixed in peanut oil or sesame oil with 2 percent aluminum monostearate [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. GAS eradication and ARF primary prevention were optimized with injection schedules that provided at least 9 to 11 days of penicillin.",
"   </p>",
"   <p>",
"    Subsequently, evaluation of GAS tonsillopharyngitis therapies has been based upon GAS eradication from the upper respiratory tract; it is assumed that such eradication is an adequate surrogate marker for efficacy in primary prevention of rheumatic fever. Antibiotic therapy can be helpful for prevention of rheumatic fever if initiated up to nine days following onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children younger than seven years of age appear to be at greatest risk of poststreptococcal glomerulonephritis. Although antibiotic therapy has efficacy for primary prevention of acute rheumatic fever, the role of antibiotics in the setting of GAS tonsillopharyngitis for prevention of poststreptococcal glomerulonephritis is not certain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14578038#H14578038\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Hematuria following upper respiratory infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     PANDAS syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS) is discussed separately. It is not clear whether antibiotic therapy for GAS pharyngitis reduces the incidence of this syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=see_link&amp;anchor=H7#H7\">",
"     \"Complications of streptococcal tonsillopharyngitis\", section on 'PANDAS syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Reducing transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of GAS transmission from an infectious case to close contacts (such as a family or school setting) is approximately 35 percent. Antibiotic treatment does have a role for preventing transmission of GAS; after 24 hours of treatment with penicillin, subsequent cultures are negative in about 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/15\">",
"     15",
"    </a>",
"    ]. Data on the duration of contagion for alternative antibiotics are not available. In untreated patients, GAS is eliminated from the upper respiratory tract by host immune factors in 50 percent of cases at one month following acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional issues related to antibiotic therapy for reducing transmission are discussed further below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy is warranted for patients with symptomatic pharyngitis if the presence of group A streptococci in the pharynx is confirmed by culture or rapid antigen detection testing (RADT). The approach to establishing the diagnosis of acute streptococcal pharyngitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation of acute pharyngitis in adults\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimicrobial therapy may also be administered to mitigate the clinical course of pharyngitis due to group C and group G streptococci. The approach to antibiotic selection is as outlined in the following sections. However, treatment need not continue for 10 days since acute rheumatic fever is not a complication of infection due to these organisms; five days of treatment is sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/2,17,18\">",
"     2,17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27080?source=see_link\">",
"     \"Group C and group G streptococcal infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, antimicrobial therapy is of no proven benefit for treatment of pharyngitis due to bacteria other than streptococcus (with the exception of relatively rare infections caused by other bacterial pathogens such as Corynebacterium diphtheriae and Neisseria gonorrhoeae). Such therapy unnecessarily exposes patients to the expense and potential hazards of antimicrobial drugs, and contributes to the emergence of antibiotic resistant bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Timing of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    epidemiologic factors point to a high index of suspicion for GAS pharyngitis while laboratory results are pending, it is appropriate to initiate empiric antimicrobial therapy. However, if laboratory testing does not confirm the diagnosis of GAS pharyngitis, antimicrobial therapy should be discontinued.",
"   </p>",
"   <p>",
"    In the natural history of GAS pharyngitis, the incubation period is two to four days. Fever and constitutional symptoms usually resolve within three to four days, even in the absence of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/16\">",
"     16",
"    </a>",
"    ]. Clinical improvement has been observed up to 48 hours sooner in patients receiving penicillin versus placebo within the first two days of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some concern that early therapy may suppress host antibody response and thereby increase risk for recurrent pharyngitis. In a study of 142 children with presumed GAS pharyngitis, those treated with penicillin at the initial office visit had a higher incidence of recurrent infection than those for whom treatment was delayed at least 48 hours (recurrent infection occurred eight times more frequently) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, delaying treatment is not warranted in most cases of GAS tonsillopharyngitis. It may be a useful strategy for patients who have frequent, recurrent, mild to moderate infections, to allow development of immunity to the infecting strain without increasing the risk of acute rheumatic fever. Antibiotic therapy delayed for up to nine days following onset of symptoms is still helpful for prevention of rheumatic fever (although may be less effective for prevention of suppurative complications) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/13\">",
"     13",
"    </a>",
"    ]. However, this approach should not be considered if the patient is severely ill or if highly virulent or rheumatogenic strains are actively circulating within a community. Patients are considered no longer contagious after 24 hours of antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotics for group A streptococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic options for treatment of GAS pharyngitis include penicillin (and other related agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    ), cephalosporins, macrolides, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/19\">",
"     19",
"    </a>",
"    ]. Sulfonamides and tetracyclines should NOT be used for treatment of GAS pharyngitis because of high rates of resistance to these agents and their frequent failure to eradicate even susceptible organisms from the pharynx.",
"   </p>",
"   <p>",
"    Intramuscular penicillin is the only therapy that has been shown to prevent initial attacks of rheumatic fever in controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. These studies were performed with procaine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    in oil containing aluminum monostearate; this preparation has since been supplanted by benzathine penicillin G. There are data suggesting that benzathine penicillin G is effective for primary prevention of rheumatic fever, although they are not definitive [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/21\">",
"     21",
"    </a>",
"    ]. Other antimicrobials have been shown to effectively eradicate GAS from the upper respiratory tract, and it is assumed that such eradication is a surrogate for efficacy in primary prevention of rheumatic fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial resistance has not been a significant issue in the treatment of GAS. No clinical isolate of GAS has demonstrated penicillin resistance, likely due to the organism's lack of altered penicillin-binding proteins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inefficient gene transfer mechanisms for resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, streptococcal strains tolerant to penicillin (eg, strains inhibited but not killed by penicillin in vitro, with ratio of MIC to the minimum bactericidal concentration of &ge;32) have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. The clinical significance of such strains is not clear; they have been isolated in the setting of outbreaks in which penicillin treatment failure was observed, but there was no difference in failure rates among tolerant and susceptible strains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6758?source=see_link\">",
"     \"Antibiotic failure in the treatment of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been reports of relatively high levels of resistance to macrolide antibiotics in some regions; given the increasing use of macrolides for treatment of upper and lower respiratory tract infections, clinicians should be cognizant of local patterns of antimicrobial resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/29-38\">",
"     29-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"     penicillin V",
"    </a>",
"    is the agent of choice for treatment of GAS pharyngitis given its proven efficacy, safety, narrow spectrum, and low cost [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/2,39-42\">",
"     2,39-42",
"    </a>",
"    ]. The appropriate duration is 10 days of therapy; dosing is outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef64596 \" href=\"UTD.htm?21/29/21981\">",
"     table 1",
"    </a>",
"    ). This approach is extrapolated from studies performed in the 1950s demonstrating that treatment of streptococcal pharyngitis with intramuscular penicillin prevents acute rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=see_link\">",
"     \"Treatment and prevention of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    is often used in place of oral penicillin in children, since the taste of the amoxicillin suspension is more palatable than that of penicillin. Some data suggest that oral amoxicillin may be marginally superior to penicillin, most likely due to better GI absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In addition, amoxicillin has activity against the common pathogens that cause otitis media (which presents concurrently with GAS tonsillopharyngitis in up to 15 percent of children, particularly those under four years of age). Dosing is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef64596 \" href=\"UTD.htm?21/29/21981\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intramuscular benzathine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (single dose) may be administered to patients who cannot complete a 10 day course of oral therapy or to patients at enhanced risk for rheumatic fever (eg, those with history of previous rheumatic heart disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    living in crowded conditions). Injections of benzathine penicillin provide bactericidal levels against GAS for 21 to 28 days. The addition of procaine penicillin alleviates some of the discomfort associated with benzathine injections and may favorably influence the initial clinical response. The preferred product is the combination of 900,000 units of benzathine penicillin G plus 300,000 units of procaine penicillin.",
"   </p>",
"   <p>",
"    Cephalosporins are acceptable alternatives in patients with recurrent GAS infection but are not recommended as first line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/45-52\">",
"     45-52",
"    </a>",
"    ]. Cephalosporins have demonstrated better microbiologic and clinical cure rates than penicillin; these differences appear to be greater among children than adults, and some favor use of first generation cephalosporins as first line therapy in this group [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. However, second and third generation cephalosporins are more expensive than penicillin and may facilitate development of antibiotic resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Recurrent infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antibiotic therapy directed against beta-lactamase producing upper respiratory tract flora (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ) remains controversial and is not indicated in patients with acute pharyngitis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/2,56,57\">",
"     2,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with beta-lactam hypersensitivity, cephalosporins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"     cefdinir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ) may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/39,44-50\">",
"     39,44-50",
"    </a>",
"    ], in the absence of history of life threatening allergic reaction; cross reactivity with penicillin is less likely for later generation cephalosporins than first generation cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/45,58-60\">",
"     45,58-60",
"    </a>",
"    ]. Macrolides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ) are an acceptable alternative for penicillin allergic patients, depending on local resistance patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/29,32-37\">",
"     29,32-37",
"    </a>",
"    ]. For the rare patient with an erythromycin-resistant strain of GAS who is unable to tolerate beta-lactam agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    is an appropriate choice [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the conventional duration of oral antibiotic therapy to achieve maximal pharyngeal GAS eradication rates is 10 days, even though patients usually improve clinically within the first few days of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. If penicillin is discontinued after three days of therapy, the probability of relapse is higher than if penicillin is discontinued after seven days of treatment (50 versus 34 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/14,16,20\">",
"     14,16,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five days of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"     cefdinir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is an acceptable alternative approach, with rates of bacteriologic and clinical cure of streptococcal pharyngitis comparable with that of the conventional 10-day course of penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/34-37,42,64-76\">",
"     34-37,42,64-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attempts to treat GAS pharyngitis with a single daily dose of penicillin have been unsuccessful. Although some data suggest that once daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    may be sufficient for treatment of GAS pharyngitis, others have shown that this approach is not adequate for effective eradication; further investigation is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. Among the alternative agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and some cephalosporins (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"     cefadroxil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"     cefdinir",
"    </a>",
"    ) are effective for eradication of pharyngeal streptococci with once daily dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/69,81-84\">",
"     69,81-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27287700\">",
"    <span class=\"h2\">",
"     Antibiotics for other organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of acute pharyngitis is outlined separately (",
"    <a class=\"graphic graphic_table graphicRef61935 \" href=\"UTD.htm?16/44/17100\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link&amp;anchor=H10774877#H10774877\">",
"     \"Evaluation of acute pharyngitis in adults\", section on 'Causes and associated clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to treatment of infection due to streptococcus other than group A, influenza, infectious mononucleosis, primary HIV infection, Neisseria gonorrhoeae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Corynebacterium diphtheriae is discussed separately. (See related topics.)",
"   </p>",
"   <p>",
"    The approach to treatment of infection due to F. necrophorum is uncertain; further study is needed to better define the role of F. necrophorum in the epidemiology of pharyngitis and the associated risk between F. necrophorum pharyngitis and Lemierre&rsquo;s syndrome. Some favor empiric treatment with penicillins or cephalosporins in the setting of negative diagnostic test results but at least three Centor criteria (fever, tonsillar exudate, swollen tender cervical adenopathy, or lack of cough) among patients 15 to 30 years of age, although it is uncertain whether this approach is effective for prevention of Lemierre&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Therefore, we favor antibiotic therapy for pharyngitis only in the setting of positive diagnostic data [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation of acute pharyngitis in adults\", section on 'Clinical predictors and Centor criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=see_link&amp;anchor=H11#H11\">",
"     \"Suppurative (septic) thrombophlebitis\", section on 'Jugular vein'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antibiotics of choice for treatment of infection due to Arcanobacterium haemolyticum are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ; data are limited to case reports and in vitro studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. In vitro studies show most strains to be susceptible to beta-lactam agents, although treatment failure may occur because of poor penetration into the intracellular space [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/88\">",
"     88",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    are also effective agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with GAS pharyngitis should have improvement in clinical symptoms within three to four days of initiating antibiotic therapy. Failure to observe a clinical response to antibiotics should prompt diagnostic reconsideration or the possibility of a suppurative complication. If acute streptococcal pharyngitis was diagnosed by rapid testing, the result may represent a false-positive finding; if the diagnosis was made by culture, the patient may be a pharyngeal carrier whose symptoms are likely attributable to an alternate process. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Carriers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In general, test of cure is not necessary for asymptomatic patients or their close contacts following completion of a course of antimicrobial therapy. The majority of patients with GAS remaining in their upper respiratory tracts after completing a course of antimicrobial therapy are streptococcus carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, follow-up test of cure is appropriate testing for asymptomatic index patients and their asymptomatic household contacts in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Individuals with history of rheumatic fever",
"     </li>",
"     <li>",
"      Individuals who develop acute pharyngitis during an outbreak of acute rheumatic fever or acute poststreptococcal glomerulonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/90\">",
"       90",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Spread of GAS among several family members",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Asymptomatic patients and asymptomatic household contacts in the above circumstances with positive laboratory results should receive a standard course of antimicrobial therapy with one of the agents outlined above [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/91\">",
"     91",
"    </a>",
"    ]. Repeat treatment should be administered with an agent with greater beta-lactamase stability than the previous agent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/56\">",
"     56",
"    </a>",
"    ]. If a penicillin was used for initial therapy, repeat treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    or a first generation cephalosporin may be used; if initial treatment was with a first generation cephalosporin, a second or third generation cephalosporin may be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link\">",
"     \"Evaluation of acute pharyngitis in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Antibiotics for group A streptococcus'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of recurrent acute pharyngitis with positive repeat diagnostic testing, there are several possible explanations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/89,91,92\">",
"     89,91,92",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistence of streptococcus carriage in the setting of viral infection",
"     </li>",
"     <li>",
"      Nonadherence with the prescribed antimicrobial regimen",
"     </li>",
"     <li>",
"      New infection with GAS acquired from household or community contacts",
"     </li>",
"     <li>",
"      Treatment failure (eg, repeat episode of pharyngitis caused by the original infecting strain); treatment failure is rare",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the setting of a second episode of acute pharyngitis with positive repeat diagnostic testing, a repeat course of treatment is appropriate (",
"    <a class=\"graphic graphic_table graphicRef64596 \" href=\"UTD.htm?21/29/21981\">",
"     table 1",
"    </a>",
"    ). Repeat treatment should be administered with an agent with greater beta-lactamase stability than the previous agent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If adherence is uncertain, intramuscular benzathine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    may be chosen as the second course of therapy. If a full course of penicillin was completed as initial therapy, a first generation cephalosporin (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"     cefadroxil",
"    </a>",
"    ) may be used; if a first generation cephalosporin was used for initial therapy, a second or third generation cephalosporin (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"     cefdinir",
"    </a>",
"    ) may be used. Alternative agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    It is not necessary to perform follow up testing after the second course of therapy unless the patient remains or becomes symptomatic, or unless special circumstances as outlined above are present. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Antibiotics for group A streptococcus'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Follow-up'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the setting of multiple recurrent episodes, it may be difficult to distinguish true GAS pharyngitis from viral pharyngitis in the setting of streptococcal carriage. It is likely that most of these patients are carriers experiencing nonstreptococcal infections. This may be discernible by evaluating for the presence of GAS during asymptomatic intervals,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by typing streptococcal isolates obtained during distinct episodes (with the expertise of a specialized laboratory). In these circumstances, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    may be beneficial since these agents have demonstrated high eradication rates for pharyngeal streptococci (",
"    <a class=\"graphic graphic_table graphicRef64596 \" href=\"UTD.htm?21/29/21981\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/56,61,93\">",
"     56,61,93",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Carriers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with as many as six GAS infections in a single year or three to four episodes in two consecutive years, tonsillectomy may be an appropriate therapeutic consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. This was illustrated in a randomized trial including 187 children with recurrent pharyngitis, of whom 95 were managed with tonsillectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/94\">",
"     94",
"    </a>",
"    ]. The incidence of pharyngitis during the first two years of follow-up was significantly lower among the tonsillectomy group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=see_link&amp;anchor=H7#H7\">",
"     \"Tonsillectomy and adenoidectomy in children\", section on 'Recurrent infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic failure in the treatment of streptococcal tonsillopharyngitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6758?source=see_link\">",
"     \"Antibiotic failure in the treatment of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Carriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, GAS resides in the oropharynx of streptococcus carriers in the absence of host immunologic response to the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/96\">",
"     96",
"    </a>",
"    ]. In temperate climates during the winter and spring, up to 20 percent of asymptomatic school-aged children may be carriers. About 25 percent of asymptomatic individuals in the households of index patients harbor GAS in their upper respiratory tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/91\">",
"     91",
"    </a>",
"    ]. Streptococcal carriage may persist for many months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6758?source=see_link&amp;anchor=H12#H12\">",
"     \"Antibiotic failure in the treatment of streptococcal tonsillopharyngitis\", section on 'Streptococcal carriage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carriers may demonstrate evidence of GAS in the upper respiratory tract during an episode of viral pharyngitis, suggesting acute streptococcal pharyngitis. In these circumstances, clinically distinguishing viral from streptococcal pharyngitis can be difficult. Useful clues may include patient age, season, local epidemiology, and the nature of presenting signs and symptoms. In addition, pharyngeal strep carriers tend to have very low ASO titers; they may be just above detectable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=see_link\">",
"     \"Evaluation of acute pharyngitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Streptococcus carriers are unlikely to spread the organism to close contacts and are at very low risk for developing suppurative complications or acute rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/96\">",
"     96",
"    </a>",
"    ]. Moreover, eradication of GAS from the upper respiratory tract of carriers is much more difficult than eradication of GAS from patient with acute infections [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/50,89,97\">",
"     50,89,97",
"    </a>",
"    ]. In general, except for the circumstances described above, streptococcus carriers do not require antimicrobial therapy. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Follow-up'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous antimicrobial prophylaxis is only appropriate for prevention of recurrent rheumatic fever in patients who have experienced a previous episode of rheumatic fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment and prevention of acute rheumatic fever\", section on 'Secondary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no vaccine against GAS available for clinical use, although development of this preventive measure is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/38/2666/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. An important area of uncertainty is whether vaccine-induced antibodies may cross-react with host tissue to produce nonsuppurative sequelae in the absence of clinical infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/57/914?source=see_link\">",
"       \"Patient information: Sore throat in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=see_link\">",
"       \"Patient information: Strep throat in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40881?source=see_link\">",
"       \"Patient information: Scarlet fever (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=see_link\">",
"       \"Patient information: Sore throat in children (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36082?source=see_link\">",
"       \"Patient information: Sore throat in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Goals of antimicrobial therapy for eradication of group A streptococcus (GAS) from the pharynx in the setting of acute streptococcal pharyngitis include (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reducing duration and severity of clinical signs and symptoms, including suppurative complications",
"     </li>",
"     <li>",
"      Reducing incidence of nonsuppurative complications (eg, acute rheumatic fever)",
"     </li>",
"     <li>",
"      Reducing transmission to close contacts by reducing infectivity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend initiating treatment with antimicrobial therapy for patients with symptomatic pharyngitis if the presence of group A streptococci in the pharynx is confirmed by culture or rapid antigen detection testing (RADT) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest initiating treatment with antimicrobial therapy for patients whose clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epidemiologic factors point to a high index of suspicion for GAS pharyngitis while laboratory results are pending (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/46/23269?source=see_link\">",
"       penicillin V",
"      </a>",
"      is the agent of choice for treatment of GAS pharyngitis in many clinical settings given its proven efficacy, safety, narrow spectrum, and low cost.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       Amoxicillin",
"      </a>",
"      is often used in place of oral penicillin in children, since the taste of the amoxicillin suspension is more palatable than that of penicillin (",
"      <a class=\"graphic graphic_table graphicRef64596 \" href=\"UTD.htm?21/29/21981\">",
"       table 1",
"      </a>",
"      ). First-generation cephalosporins are an acceptable alternative to penicillin and amoxicillin in the setting of treatment failure or beta-lactam hypersensitivity. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although most patients improve clinically within the first few days of treatment, the conventional duration of oral antibiotic therapy is 10 days to achieve maximal pharyngeal GAS eradication rates. Intramuscular benzathine",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      may be administered to patients who cannot complete a 10-day course of oral therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT treating with antibiotics for pharyngitis in the absence of positive diagnostic culture data (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      for treatment of pharyngitis due to A. haemolyticum (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27287700\">",
"       'Antibiotics for other organisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, test of cure is not necessary for asymptomatic patients or their close contacts following completion of a course of antimicrobial therapy, except in unique circumstances. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a repeat course of treatment for patients with a repeat episode of acute pharyngitis and positive repeat diagnostic testing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients warranting a repeat course of treatment may receive an agent with greater beta-lactamase stability than the previous agent. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Recurrent infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are long-term streptococcal carriers may develop multiple episodes of pharyngitis due to viral infection. In such cases, repeatedly positive cultures or rapid antigen tests for GAS may be misleading, and further treatment for streptococcal pharyngitis may not be warranted. Carriers are unlikely to spread the organism to close contacts and are at very low risk for developing suppurative complications or acute rheumatic fever. Moreover, eradication of GAS from the upper respiratory tract of carriers can be difficult and is not necessary. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Carriers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/1\">",
"      Wessels MR. Clinical practice. Streptococcal pharyngitis. N Engl J Med 2011; 364:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/2\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/3\">",
"      Pichichero ME. Controversies in the treatment of streptococcal pharyngitis. Am Fam Physician 1990; 42:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/4\">",
"      Pichichero ME. Group A streptococcal tonsillopharyngitis: cost-effective diagnosis and treatment. Ann Emerg Med 1995; 25:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/5\">",
"      Randolph MF, Gerber MA, DeMeo KK, Wright L. Effect of antibiotic therapy on the clinical course of streptococcal pharyngitis. J Pediatr 1985; 106:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/6\">",
"      Pichichero ME, Disney FA, Talpey WB, et al. Adverse and beneficial effects of immediate treatment of Group A beta-hemolytic streptococcal pharyngitis with penicillin. Pediatr Infect Dis J 1987; 6:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/7\">",
"      Krober MS, Bass JW, Michels GN. Streptococcal pharyngitis. Placebo-controlled double-blind evaluation of clinical response to penicillin therapy. JAMA 1985; 253:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/8\">",
"      Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev 2000; :CD000023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/9\">",
"      Gilbert GG, Pruitt BE. School health education in the United States. Hygie 1984; 3:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/10\">",
"      Potter EV, Svartman M, Mohammed I, et al. Tropical acute rheumatic fever and associated streptococcal infections compared with concurrent acute glomerulonephritis. J Pediatr 1978; 92:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/11\">",
"      McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis 2004; 4:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/12\">",
"      McDonald MI, Towers RJ, Andrews RM, et al. Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. Clin Infect Dis 2006; 43:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/13\">",
"      CATANZARO FJ, STETSON CA, MORRIS AJ, et al. The role of the streptococcus in the pathogenesis of rheumatic fever. Am J Med 1954; 17:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/14\">",
"      DENNY FW, WANNAMAKER LW, BRINK WR, et al. Prevention of rheumatic fever; treatment of the preceding streptococcic infection. J Am Med Assoc 1950; 143:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/15\">",
"      Snellman LW, Stang HJ, Stang JM, et al. Duration of positive throat cultures for group A streptococci after initiation of antibiotic therapy. Pediatrics 1993; 91:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/16\">",
"      BRINK WR, RAMMELKAMP CH Jr, DENNY FW, WANNAMAKER LW. Effect in penicillin and aureomycin on the natural course of streptococcal tonsillitis and pharyngitis. Am J Med 1951; 10:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/17\">",
"      Meier FA, Centor RM, Graham L Jr, Dalton HP. Clinical and microbiological evidence for endemic pharyngitis among adults due to group C streptococci. Arch Intern Med 1990; 150:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/18\">",
"      Turner JC, Hayden FG, Lobo MC, et al. Epidemiologic evidence for Lancefield group C beta-hemolytic streptococci as a cause of exudative pharyngitis in college students. J Clin Microbiol 1997; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/19\">",
"      Betriu C, Sanchez A, Gomez M, et al. Antibiotic susceptibility of group A streptococci: a 6-year follow-up study. Antimicrob Agents Chemother 1993; 37:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/20\">",
"      WANNAMAKER LW, RAMMELKAMP CH Jr, DENNY FW, et al. Prophylaxis of acute rheumatic fever by treatment of the preceding streptococcal infection with various amounts of depot penicillin. Am J Med 1951; 10:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/21\">",
"      CHAMOVITZ R, CATANZARO FJ, STETSON CA, RAMMELKAMP CH Jr. Prevention of rheumatic fever by treatment of previous streptococcal infections. I. Evaluation of benzathine penicillin G. N Engl J Med 1954; 251:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/22\">",
"      Coonan KM, Kaplan EL. In vitro susceptibility of recent North American group A streptococcal isolates to eleven oral antibiotics. Pediatr Infect Dis J 1994; 13:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/23\">",
"      Horn DL, Zabriskie JB, Austrian R, et al. Why have group A streptococci remained susceptible to penicillin? Report on a symposium. Clin Infect Dis 1998; 26:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/24\">",
"      Van Asselt GJ, Mouton RP. Detection of penicillin tolerance in Streptococcus pyogenes. J Med Microbiol 1993; 38:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/25\">",
"      Brett MS. Antibiotic susceptibilities and penicillin tolerance of group A streptococci isolated in New Zealand in 1990. J Antimicrob Chemother 1994; 33:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/26\">",
"      Dagan R, Ferne M, Sheinis M, et al. An epidemic of penicillin-tolerant group A streptococcal pharyngitis in children living in a closed community: mass treatment with erythromycin. J Infect Dis 1987; 156:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/27\">",
"      Stevens DL, Yan S, Bryant AE. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993; 167:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/28\">",
"      Kaplan EL, Johnson DR. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group a streptococci from children with acute pharyngitis. Pediatrics 2001; 108:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/29\">",
"      Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002; 346:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/30\">",
"      Sepp&auml;l&auml; H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/31\">",
"      Cornaglia G, Ligozzi M, Mazzariol A, et al. Resistance of Streptococcus pyogenes to erythromycin and related antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance. Clin Infect Dis 1998; 27 Suppl 1:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/32\">",
"      Derrick CW, Dillon HC. Erythromycin therapy for streptococcal pharyngitis. Am J Dis Child 1976; 130:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/33\">",
"      Richter SS, Heilmann KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005; 41:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/34\">",
"      Bachand RT Jr. A comparative study of clarithromycin and penicillin VK in the treatment of outpatients with streptococcal pharyngitis. J Antimicrob Chemother 1991; 27 Suppl A:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/35\">",
"      Still JG, Hubbard WC, Poole JM, et al. Comparison of clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal pharyngitis and review of currently available alternative antibiotic therapies. Pediatr Infect Dis J 1993; 12:S134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/36\">",
"      Hooton TM. A comparison of azithromycin and penicillin V for the treatment of streptococcal pharyngitis. Am J Med 1991; 91:23S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/37\">",
"      Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Clin Infect Dis 2005; 40:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/38\">",
"      Logan LK, McAuley JB, Shulman ST. Macrolide treatment failure in streptococcal pharyngitis resulting in acute rheumatic fever. Pediatrics 2012; 129:e798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/39\">",
"      Gerber MA, Spadaccini LJ, Wright LL, et al. Twice-daily penicillin in the treatment of streptococcal pharyngitis. Am J Dis Child 1985; 139:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/40\">",
"      Snow V, Mottur-Pilson C, Cooper RJ, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults. Ann Intern Med 2001; 134:506.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Group A Streptococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/42\">",
"      Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/43\">",
"      Gopichand I, Williams GD, Medendorp SV, et al. Randomized, single-blinded comparative study of the efficacy of amoxicillin (40 mg/kg/day) versus standard-dose penicillin V in the treatment of group A streptococcal pharyngitis in children. Clin Pediatr (Phila) 1998; 37:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/44\">",
"      Curtin-Wirt C, Casey JR, Murray PC, et al. Efficacy of penicillin vs. amoxicillin in children with group A beta hemolytic streptococcal tonsillopharyngitis. Clin Pediatr (Phila) 2003; 42:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/45\">",
"      Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005; 115:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/46\">",
"      Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. Clin Infect Dis 2004; 38:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/47\">",
"      Casey JR, Pichichero ME. Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. Pediatrics 2004; 113:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/48\">",
"      Bisno AL. Are cephalosporins superior to penicillin for treatment of acute streptococcal pharyngitis? Clin Infect Dis 2004; 38:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/49\">",
"      Shulman ST, Gerber MA. So what's wrong with penicillin for strep throat? Pediatrics 2004; 113:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/50\">",
"      Gerber MA, Tanz RR, Kabat W, et al. Potential mechanisms for failure to eradicate group A streptococci from the pharynx. Pediatrics 1999; 104:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/51\">",
"      Linder JA, Stafford RS. Antibiotic treatment of adults with sore throat by community primary care physicians: a national survey, 1989-1999. JAMA 2001; 286:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/52\">",
"      Pavesio D, Pecco P, Peisino MG. Short-term treatment of streptococcal tonsillitis with ceftriaxone. Chemotherapy 1988; 34 Suppl 1:34.",
"     </a>",
"    </li>",
"    <li>",
"     Evidence-Based Pediatric Infectious Diseases, Isaacs D, Elliott E, Corlbert R, et al (Eds), Blackmill Publishing, Victoria, Austrailia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/54\">",
"      Pichichero ME, Hoeger W, Marsocci SM, et al. Variables influencing penicillin treatment outcome in streptococcal tonsillopharyngitis. Arch Pediatr Adolesc Med 1999; 153:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/55\">",
"      Kaplan EL, Oakes JM, Johnson DR. Unexpected individual clinical site variation in eradication rates of group a streptococci by penicillin in multisite clinical trials. Pediatr Infect Dis J 2007; 26:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/56\">",
"      Kaplan EL, Johnson DR. Eradication of group A streptococci from the upper respiratory tract by amoxicillin with clavulanate after oral penicillin V treatment failure. J Pediatr 1988; 113:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/57\">",
"      Brook I. Treatment of patients with acute recurrent tonsillitis due to group A beta-haemolytic streptococci: a prospective randomized study comparing penicillin and amoxycillin/clavulanate potassium. J Antimicrob Chemother 1989; 24:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/58\">",
"      American Academy of Pediatrics. Subcommittee on Management of Sinusitis and Committee on Quality Improvement. Clinical practice guideline: management of sinusitis. Pediatrics 2001; 108:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/59\">",
"      Pichichero ME, Casey JR. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg 2007; 136:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/60\">",
"      Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics 2013; 131:e964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/61\">",
"      Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group A streptococci. J Pediatr 1991; 119:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/62\">",
"      Kaplan EL, Gooch III WM, Notario GF, Craft JC. Macrolide therapy of group A streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in streptococcal eradication than 5 days (azithromycin). Clin Infect Dis 2001; 32:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/63\">",
"      Altamimi S, Khalil A, Khalaiwi KA, et al. Short-term late-generation antibiotics versus longer term penicillin for acute streptococcal pharyngitis in children. Cochrane Database Syst Rev 2012; 8:CD004872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/64\">",
"      Cohen R, Levy C, Doit C, et al. Six-day amoxicillin vs. ten-day penicillin V therapy for group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 1996; 15:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/65\">",
"      Peyramond D, Portier H, Geslin P, Cohen R. 6-day amoxicillin versus 10-day penicillin V for group A beta-haemolytic streptococcal acute tonsillitis in adults: a French multicentre, open-label, randomized study. The French Study Group Clamorange. Scand J Infect Dis 1996; 28:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/66\">",
"      Gerber MA, Tanz RR. New approaches to the treatment of group A streptococcal pharyngitis. Curr Opin Pediatr 2001; 13:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/67\">",
"      McCarty J, Hedrick JA, Gooch WM. Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. Adv Ther 2000; 17:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/68\">",
"      Tack KJ, Henry DC, Gooch WM, et al. Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study Group. Antimicrob Agents Chemother 1998; 42:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/69\">",
"      Pichichero ME, Gooch WM, Rodriguez W, et al. Effective short-course treatment of acute group A beta-hemolytic streptococcal tonsillopharyngitis. Ten days of penicillin V vs 5 days or 10 days of cefpodoxime therapy in children. Arch Pediatr Adolesc Med 1994; 148:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/70\">",
"      Pichichero ME. Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? Pediatr Infect Dis J 1993; 12:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/71\">",
"      Pichichero ME. Shortened regimens for pharyngitis/tonsillitis. Hosp Pract 1996; 31(Suppl 1):14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/72\">",
"      Falagas ME, Vouloumanou EK, Matthaiou DK, et al. Effectiveness and safety of short-course vs long-course antibiotic therapy for group a beta hemolytic streptococcal tonsillopharyngitis: a meta-analysis of randomized trials. Mayo Clin Proc 2008; 83:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/73\">",
"      Mehra S, van Moerkerke M, Welck J, et al. Short course therapy with cefuroxime axetil for group A streptococcal tonsillopharyngitis in children. Pediatr Infect Dis J 1998; 17:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/74\">",
"      Boccazzi A, Tonelli P, De'Angelis M, et al. Short course therapy with cefitbuten versus azithromycin in pediatric streptococcal pharyngitis. Pediatr Infect Dis J 2000; 19:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/75\">",
"      Casey JR, Pichichero ME. Metaanalysis of short course antibiotic treatment for group a streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2005; 24:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/76\">",
"      Adam D, Scholz H, Helmerking M. Short-course antibiotic treatment of 4782 culture-proven cases of group A streptococcal tonsillopharyngitis and incidence of poststreptococcal sequelae. J Infect Dis 2000; 182:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/77\">",
"      Shvartzman P, Tabenkin H, Rosentzwaig A, Dolginov F. Treatment of streptococcal pharyngitis with amoxycillin once a day. BMJ 1993; 306:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/78\">",
"      Feder HM Jr, Gerber MA, Randolph MF, et al. Once-daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics 1999; 103:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/79\">",
"      Clegg HW, Ryan AG, Dallas SD, et al. Treatment of streptococcal pharyngitis with once-daily compared with twice-daily amoxicillin: a noninferiority trial. Pediatr Infect Dis J 2006; 25:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/80\">",
"      Pichichero ME, Casey JR, Block SL, et al. Pharmacodynamic analysis and clinical trial of amoxicillin sprinkle administered once daily for 7 days compared to penicillin V potassium administered four times daily for 10 days in the treatment of tonsillopharyngitis due to Streptococcus pyogenes in children. Antimicrob Agents Chemother 2008; 52:2512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/81\">",
"      Pichichero ME, Disney FA, Aronovitz GH, et al. Randomized, single-blind evaluation of cefadroxil and phenoxymethyl penicillin in the treatment of streptococcal pharyngitis. Antimicrob Agents Chemother 1987; 31:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/82\">",
"      Block SL, Hedrick JA, Tyler RD. Comparative study of the effectiveness of cefixime and penicillin V for the treatment of streptococcal pharyngitis in children and adolescents. Pediatr Infect Dis J 1992; 11:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/83\">",
"      Adam D, Hostalek U, Tr&ouml;ster K. 5-day cefixime therapy for bacterial pharyngitis and/or tonsillitis: comparison with 10-day penicillin V therapy. Cefixime Study Group. Infection 1995; 23 Suppl 2:S83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/84\">",
"      Nemeth MA, Gooch WM 3rd, Hedrick J, et al. Comparison of cefdinir and penicillin for the treatment of pediatric streptococcal pharyngitis. Clin Ther 1999; 21:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/85\">",
"      Centor RM, Allison JJ, Cohen SJ. Pharyngitis management: defining the controversy. J Gen Intern Med 2007; 22:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/86\">",
"      Centor RM. Expand the pharyngitis paradigm for adolescents and young adults. Ann Intern Med 2009; 151:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/87\">",
"      Mackenzie A, Fuite LA, Chan FT, et al. Incidence and pathogenicity of Arcanobacterium haemolyticum during a 2-year study in Ottawa. Clin Infect Dis 1995; 21:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/88\">",
"      Carlson P, Renkonen OV, Kontiainen S. Arcanobacterium haemolyticum and streptococcal pharyngitis. Scand J Infect Dis 1994; 26:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/89\">",
"      Kaplan EL, Gastanaduy AS, Huwe BB. The role of the carrier in treatment failures after antibiotic for group A streptococci in the upper respiratory tract. J Lab Clin Med 1981; 98:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/90\">",
"      Gerber MA. Treatment failures and carriers: perception or problems? Pediatr Infect Dis J 1994; 13:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/91\">",
"      Schwartz RH, Wientzen RL Jr, Pedreira F, et al. Penicillin V for group A streptococcal pharyngotonsillitis. A randomized trial of seven vs ten days' therapy. JAMA 1981; 246:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/92\">",
"      Gerber MA, Randolph MF, Chanatry J, et al. Once daily therapy for streptococcal pharyngitis with cefadroxil. J Pediatr 1986; 109:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/93\">",
"      Orrling A, Stjernquist-Desatnik A, Schal&eacute;n C, Kamme C. Clindamycin in persisting streptococcal pharyngotonsillitis after penicillin treatment. Scand J Infect Dis 1994; 26:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/94\">",
"      Paradise JL, Bluestone CD, Bachman RZ, et al. Efficacy of tonsillectomy for recurrent throat infection in severely affected children. Results of parallel randomized and nonrandomized clinical trials. N Engl J Med 1984; 310:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/95\">",
"      Alho OP, Koivunen P, Penna T, et al. Tonsillectomy versus watchful waiting in recurrent streptococcal pharyngitis in adults: randomised controlled trial. BMJ 2007; 334:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/96\">",
"      Kaplan EL. The group A streptococcal upper respiratory tract carrier state: an enigma. J Pediatr 1980; 97:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/97\">",
"      Shulman ST, Gerber MA, Tanz RR, Markowitz M. Streptococcal pharyngitis: the case for penicillin therapy. Pediatr Infect Dis J 1994; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/98\">",
"      McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005; 41:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/38/2666/abstract/99\">",
"      Pichichero ME. Group A streptococcal vaccines. JAMA 2004; 292:738.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8049 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2666=[""].join("\n");
var outline_f2_38_2666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Reducing clinical symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reducing nonsuppurative complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - PANDAS syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Reducing transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Timing of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotics for group A streptococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27287700\">",
"      Antibiotics for other organisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Carriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8049\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8049|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/29/21981\" title=\"table 1\">",
"      Treatment streptococcal pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/44/17100\" title=\"table 2\">",
"      Causes of acute pharyngitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6758?source=related_link\">",
"      Antibiotic failure in the treatment of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=related_link\">",
"      Complications of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=related_link\">",
"      Epidemiology and pathogenesis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5738?source=related_link\">",
"      Evaluation of acute pharyngitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27080?source=related_link\">",
"      Group C and group G streptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40881?source=related_link\">",
"      Patient information: Scarlet fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36082?source=related_link\">",
"      Patient information: Sore throat in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/57/914?source=related_link\">",
"      Patient information: Sore throat in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/22/3427?source=related_link\">",
"      Patient information: Sore throat in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=related_link\">",
"      Patient information: Strep throat in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=related_link\">",
"      Suppurative (septic) thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=related_link\">",
"      Treatment and prevention of acute rheumatic fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_38_2667="Reviewing medications";
var content_f2_38_2667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A step-wise approach to reviewing medications for older adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Review current drug therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discontinue potentially unnecessary therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider adverse drug events as a potential cause for any new symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider non-pharmacological approaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substitute with safer alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce the dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use beneficial therapies when indicated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rochon, P, JH, Gurwitz. Drug Therapy. The Lancet 1995; 346:32. Copyright &copy; 1995 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2667=[""].join("\n");
var outline_f2_38_2667=null;
var title_f2_38_2668="Histopathology cervical cancer";
var content_f2_38_2668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65824&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histopathology of cervical cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        A. Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Large cell, keratinizing squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Large cell, non-keratinizing squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Verrucous carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Papillary squamous and transitional cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lymphoepithelioma-like carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        B. Adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mucinous, endocervical variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mucinous, intestinal type, signet ring variant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mucinous, adenoma malignum (minimal deviation variant)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mucinous, villoglandular adenocarcinoma (well differentiated)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Endometriod type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Clear cell type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Papillary serous type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mesonephric type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. Adenosquamous carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. Adenoid cystic carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E. Neuroendocrine (carcinoid, small cell, large cell)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        F. Undifferentiated carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        G. Mixed epithelial and mesenchymal tumors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in: Ngan HYS, et al. Int J Gynecol Obstet 2000; 70:207.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2668=[""].join("\n");
var outline_f2_38_2668=null;
var title_f2_38_2669="Associations retinal vasculitis";
var content_f2_38_2669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders associated with retinal vasculitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Systemic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Behcet's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Granulomatosis with polyangiitis (Wegener's)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Relapsing polychodritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Giant cell arteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polyarteritis nodosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Whipple's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Crohn's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            HLA-B27 associated conditions",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxoplasmosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes zoster",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute retinal necrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coccidiomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amoebiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Candidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leptospirosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ricketsia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brucellosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lyme disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Human immunodeficiency virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxocariasis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Ocular disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Birdshot retinochoroidopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pars planitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eale's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Retinal arteriolitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Behcet's sine systemic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sympathetic ophthalmia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2669=[""].join("\n");
var outline_f2_38_2669=null;
var title_f2_38_2670="Sellheim spoon";
var content_f2_38_2670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    Sellheim spoon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 176px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2670=[""].join("\n");
var outline_f2_38_2670=null;
var title_f2_38_2671="Peptic esophageal stricture";
var content_f2_38_2671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peptic esophageal stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 241px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Esophagram demonstrates 6 cm long distal esophageal peptic stricture with associated nodularity (arrows). Note the granular pattern of the esophagus consistent with esophagitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Anita E Spiess, MD and Peter J Kahrilas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_38_2671=[""].join("\n");
var outline_f2_38_2671=null;
